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Selective and efficient C-H bond oxidation using conventional organic methods is a 
challenging task. As biocatalysts, cytochrome P450 enzymes provide an enzymatic route for 
the oxidation of unreactive carbon-hydrogen (C-H) bonds. CYP102A1 (P450Bm3) from the 
Bacillus megaterium bacterium is one of the most studied members of the P450 superfamily 
because of its solubility and high activity towards fatty acids (C12-15). P450Bm3 is a self-
sufficient enzyme and only needs NADPH (as a source of electrons) and O2 for oxidation 
reactions. 
 The primary subject of this thesis is exploring the regio- and stereoselectivity of four rate 
accelerating variants of P450Bm3: KT2 (A191T/N239H/I259V/A276T/L353I), R19 
(R47L/Y51F/H171L/Q307H/N319Y), RLYFIP (R47L/Y51F/I401P) and RLYFAP 
(R47L/Y51F/A330P), in the oxidation of substituted benzenes that contain different alkyl and 
vinyl groups. Whereas wild type (WT) P450Bm3 showed low activity for the oxidation of these 
substrates, the mutated variants showed high product formation rates and maintained the 
regioselectivity of WT P450Bm3. However, the RLYFAP variant, which contains an 
alanine330 (A330) to proline mutation (A330P) resulted in different regioselectivity. For 
example, oxidation of 3-ethyltoluene with RLYFAP occurred at the benzene ring and generated 
a phenol product (2-ethyl-4-methylphenol, 92 %) in contrast to the WT, R19, KT2 and RLYFIP 
variants, which oxidised the alkyl side chain and the aromatic ring with equal yields. 
The effects of polyfluorinated fatty acids (PFCs) on the activity and selectivity of P450Bm3 
variants were also studied. Decoy molecules are dummy substrates with a similar structure to 
fatty acids. Therefore, the carboxylate group interacts with key residues of P450Bm3 (Arg47 




non-native species to get close to the haem centre.  The addition of decoy molecules to the 
variants increased the range of the substrates along with providing higher productivity. The 
regioselectivity of the enzyme that catalysed oxidations was maintained and the 
stereoselectivity slightly improved.  For example, the addition of PFC10 to the WT Bm3 in the 
oxidation of ethylbenzene enhanced the enantiomeric excess from 48 % to 68% (R). 
4-Hydroxyisophorone is a flavour and fragrance compound and the selective oxidation of 
isophorone to (R)-4-hydroxyisophorone with RLYFIP, R19, WT and GVQ 
(A74G/F87V/L188Q) variants was studied. GVQ and RLYFIP showed a 280-fold increase in 
oxidation activity over WT. Addition of decoy molecules further increased oxidation activity 
with the majority of the variants. However, decoy molecules reduced the activity of the GVQ 
variant for the reaction. The product distributions with the variants were almost identical and 
(R)-4-hydroxyisophorone was the main product with > 90 % ee. 
 The decoy molecules (PFC3-PFC10) were employed in the hydroxylation of cycloalkanes 
(C5-C10) to investigate how the combination of different sizes of substrates and decoy 
molecules changes the oxidation activity of the WT P450Bm3 and its variants. The highest 
product formation was observed with cyclooctane. The combination of decoy molecules with 
WT P450Bm3 and other variants increased productivity. By increasing the size of the decoy 
molecule, higher activity was achieved, and PFC10 was the best decoy molecules in all 
variants, excluding the GVQ variant, which showed lower activity with decoy molecules. 
Second generation decoy molecules, which are a combination of first-generation decoy 
molecules (PFC9) and amino acids were also employed in the hydroxylation of cycloalkanes 
as well and significantly improved the activity of P450Bm3WT in the oxidation of smaller 




and cyclohexanol). It is hypothesised that the incorporation of amino acid into the decoy 
molecules better-allowed interaction with the active site of the P450Bm3. 
A single mutation of threonine 268, which is involved in dioxygen activation, to glutamic acid 
(T268E) was made to the haem domain of P450Bm3 WT. This mutant was found to convert 
WT Bm3 into an H2O2-dependent variant (Bm3T268E or Bm3TE). The activity of Bm3TE in 
the oxidation of styrene, ethylbenzene and methylthiobenzene in the presence of H2O2 was 
tested and compared with the holoenzymes (WT and R19 variants). While no activity was 
observed with WT and R19 variants, Bm3TE successfully oxidised the substrates above. The 
addition of the second generation decoy molecules to holoenzymes enhanced the oxidation 
activity, but they did not significantly improve the activity of Bm3TE. The regioselectivity was 
maintained with the Bm3TE variant although stereoselectivity of ethylbenzene oxidation 
changed and was more in favour of the (S) enantiomer. 
Finally, encapsulation of Bm3TE in metal-organic frameworks (MOFs) was studied. Since 
Zeolitic imidazolate frameworks (ZIFs) can be synthesised under mild conditions, ZIF-8 and 
ZIF-90 crystals were the candidates MOFs for in-situ encapsulation of Bm3TE to increase 
thermal and chemical stability. It was found that Bm3TE lost almost all its activity in the 
process of encapsulation. Therefore, ZIF-8 and ZIF-90 crystals were pre-synthesised to study 
immobilisation of Bm3TE on the surface. But again, no activity was observed. 
Given that organic ligands and MOF surface were a challenge during the immobilisation of 
Bm3TE, bacterial compartments were used for encapsulation of P450Bm3. Two encapsulin 
compartments from Thermotoga maritima (Tm) and Myxococcus xanthus (Mx) were employed 
for capsid formation around the P450Bm3 R19 variant. Bm3 R19 was used as a cargo protein 
after being tagged with short targeting peptides (TPs) of the natural cargo of Tm and Mx 




level of product formation were observed with the P450Bm3 R19 in the Mx encapsulin. Future 
studies will include modification of the encapsulin plasmids and conditions of protein 
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Cytochrome P450 enzymes are a superfamily of haem monooxygenases that can be found in 
almost all living creatures from prokaryotes to eukaryotes1. The name “P450” originates from 
the red pigmentation of the enzyme when the haem moiety in its reduced ferrous form binds 
carbon monoxide, resulting in a Soret band absorption at 450 nm2-4. As of 2018, more than 
41000 members of this superfamily have been named according to the family and subfamily 
nomenclature of Nebert et al.5. A P450 family is defined such that its members have at least 40 
percent similarity in their amino acid sequences; these are denoted by a number after the CYP 
prefix. When the amino acid sequence similarity is above 55 percent, genes are grouped into 
subfamilies which are represented by a letter after the family name and following by the gene 
identifier number5-8. For example, the P450 CYP102A1 from Bacillus megaterium belongs to 
family 102 and is the first member of subfamily A. 
The first cytochrome P450 structure characterized was P450cam (CYP101A1) which was 
reported by Poulos in the 1980s9, 10. By comparing the structures of P450s from different 
families, it has been observed that this class of enzymes has a highly conserved general fold. 
The structure is more conserved around the haem centre, especially in the L and I helices11, 
which contain several catalytically essential residues. The metal centre in cytochrome P450 
enzymes consists of a central iron (ІІІ) atom coordinated to four nitrogen ligand donors from a 





the resting state. In this resting state, the low-spin iron is in the ferric oxidation state (Figure 1. 
1)12.  
 
Figure 1. 1 All P450 haem-thiolate enzymes consist of iron (III) protoporphyrin IX linked to 
a Cys ligand12. 
1.2 Catalytic cycle of P450 enzymes 
P450 enzymes catalyse a diverse range of reactions such as heteroatom dealkylation, 
heteroatom oxygenation, epoxide formation, and aromatic oxidation13, 14. Nonetheless, the 
most common reaction catalysed by P450 enzymes is the hydroxylation of C-H bonds. As 
monooxygenases, cytochrome P450 enzymes utilise atmospheric dioxygen to insert a single 
oxygen atom into the substrate with a concomitant reduction of the other oxygen atom to a 
molecule of water15 (Equation 1. 1). However, there are some exceptions like the peroxygenase 
family of P450, CYP152, which employ H2O2 instead of molecular oxygen for the 
hydroxylation of fatty acids11, 16, 17. 
Equation 1. 1 Hydroxylation of a C-H bond by a P450 enzyme.                                                              
R-H + O2 + 2e
- + 2H+ → R-OH + H2O        
The source of electrons required for this reaction is generally nicotinamide adenine 






Figure 1. 2 The catalytic cycle of a P450 enzyme shows the substrate binding, electron transfer, 
oxygen binding and activation steps. Compound I (VII) is the active oxidant.  
Upon substrate binding, the distal water ligand of the resting state (I) is displaced, yielding a 
five-coordinated ferric species (II). The first electron transfer then occurs, and the ferric iron is 
reduced to the ferrous state (III). This reduction facilitates the binding of the molecular oxygen 
as the sixth ligand to yield an oxy-bound species (IV). The second electron is then transferred, 
followed by protonation of the distal oxygen atom to form a hydroperoxy complex (V-VI). The 
next protonation leads to O-O bond cleavage with the release of one molecule of water, 
generating the iron-oxo radical cation intermediate (VII, Compound I). This highly reactive 
oxygen species abstracts a proton from the substrate to form a radical and Compound II (Figure 
1. 3). This radical attacks the Fe-OH group of Compound II, allowing for homolytic O-Fe 
cleavage and producing a ferric complex (VII-VIII). The oxidised substrate is released, and a 






Figure 1. 3 The radical rebound mechanism of Compound I to hydroxylate the substrate. 
The catalytic cycle of P450 enzymes (Figure 1. 2) requires an auxiliary electron transfer protein 
to provide electrons from NAD(P)H to the reduced ferric haem (II) and ferrous-dioxy (III) 
complexes. There are different electron transfer systems. Initial classification of electron 
transfer systems of P450 enzymes consisted of two major types (Figure 1. 4). However, 
subsequent studies have identified that electron transfer systems are more diverse and can be 
classified into ten groups24-26. The first class contains most of the bacterial P450 systems and 
the mitochondrial P450s from eukaryotes. Systems in this class require three proteins; the P450, 
an FAD (flavin adenine dinucleotide)-containing ferredoxin reductase and an iron-sulphur 
ferredoxin. Generally in a class I system, the electron is transferred from the NAD(P)H electron 
source to the FAD source, then through the FAD to the Fe2S2 cluster and finally to the haem 
centre in P450 enzymes. In bacterial P450 systems, all three proteins are typically water 
soluble; however, in eukaryote mitochondrial systems, only the ferredoxin is water-soluble27, 
28 29. Examples of class I systems include the bacterial system P450cam (CYP101) from 
Pseudomonas putida and mitochondrial P450scc (CYP11A1)30.  
The class II system is found with mammalian P450s and includes a P450 and a diflavin 
reductase. This species contains both the organic cofactors FAD and FMN (flavin 
mononucleotide), which transfer electrons to the P450 enzyme. Both enzymes in these class II 
systems are membrane-bound (Figure 1. 4, b and c); therefore, they have a lower solubility in 





P450Bm3 (CYP102A1) is from class VIII and was the first self-sufficient P450 that was 
discovered. In P450Bm3, the reductase domain is fused to the haem domain, and the enzyme 
only needs oxygen and NADPH as a source of electrons (Figure 1. 4 d). P450Bm3 has been 
reported as a dimer in solution30. Studies by Munro et al. showed that Bm3 was required to be 
in its dimeric form to be catalytically active31. The reductase domain contains FAD and FMN, 
and since these are bound in the same enzyme as the haem, a reorientation of FMN is required 
to allow it to dock to the haem for successful electron transfer. The flexible nature of these 
regions of this protein is hypothetically one of the reasons that no crystal structure of full-length 
P450Bm3 has been reported32.  
 
Figure 1. 4 Electron transfer system in P450 enzymes. a) bacterial class I and b) eukaryotic 
class I, c) mammalian class II and d) the P450Bm3 system. In eukaryotic systems, proteins are 







1.3 P450 reactions 
Compound I is widely believed to be responsible for the C-H bond oxidation in P450 enzymes, 
and its role in hydroxylation has been extensively studied33-35. However, other intermediates 
have been suggested for specific P450 enzymes reactions because of their different reactivity 
profiles. For example, the electrophilic Compound 0 has been reported to be able to catalyse 
alkene epoxidation34, 36-38. The most common reactions catalysed by P450 enzymes are briefly 
described below14, 39-42. 
1.3.1 Hydroxylation 
C-H bond oxidation is one of the most challenging chemical reactions due to the high stability 
of this bond. This unreactive bond often requires harsh reaction conditions like high 
temperature and pressure. Enzymatic approaches, specifically, using monooxygenase enzymes, 
have emerged as an alternative method for C-H bond oxidation. The initially proposed 
mechanism for C-H oxidation by Groves et al. involved hydrogen abstraction from the 
substrate by Compound I, followed by rebounding of the radical to generate the ferric (III) 
complex (Figure 1. 3)43-45. Experiments determining the kinetic isotope effect (KIE) for many 
P450-catalysed transformations, supported the radical mechanism46, but the existence of a 
radical intermediate was cast into doubt using ultrafast radical clocks47-49. The lifetime of the 
substrates as intermediates calculated using the ultrafast radical clock was closer to that 
expected for a transition state than a reaction intermediate50-52. 
Based on DFT calculations, the spin state of Compound I has been suggested to control whether 
the hydroxylation proceeds via a carbocation or a radical state53 (Figure 1. 5). Using these 
calculations, the short radical lifetime observed in certain experiment is explained by the 





lifetime attributed to the high energy barrier in the high spin state (quartet). The high energy 
barrier in the radical rebound mechanism for the high spin pathway leads to an alternative 
reaction involving a cationic intermediate, while this barrier for the low spin state is negligible. 
Therefore when Compound I is low spin, the radical rebound mechanism is favoured (Figure 
1. 5)53. 
Figure 1. 5 The DFT-based mechanism for hydroxylation from high spin (HS: 4A2u, solid line) 
and low spin states (LS: 2A2u, dashed line) of Compound I. TS refers to the transition state. 
1.3.2 Epoxidation of alkenes  
Epoxidation of alkenes by cytochrome P450 enzymes usually display some stereoselectivity, 
which originally suggested a concerted mechanism by the enzyme47, 54 (Figure 1. 6).  
 





Subsequently, two species have been reported to be responsible for epoxidation by the haem 
domain, Compound I and Compound 0. The pathway using Compound I is again proposed to 
use a two-state reactivity model (TSR) of the low and high spin states55 (Figure 1. 7). The low 
spin state has a low energy barrier and generates a radical intermediate. The high spin state has 
a higher energy barrier and generates a carbocation. This larger barrier for the high spin state 
increases its lifetime, which leads to a more stereoselective product56-59. Compound 0 was 
calculated to have single state reactivity (SSR), and its energy barrier for epoxidation was larger 
than for Compound I55. Therefore, based on DFT calculations, Compound 0 was proposed to 
not be an oxidant by itself 55.  
Figure 1. 7 The epoxidation of alkanes by Compound I through radical (top) and cationic 
(bottom) pathways. 
Another pathway reported from the oxidation of alkenes by P450 enzymes is the formation of 
aldehydes. Aldehyde formation can be explained by an electron transfer between a C-radical 





the less substituted C, and one of the substitutions migrate to generate an aldehyde (Figure 1. 
8)55.  
 
Figure 1. 8 Mechanism of aldehyde formation instead of epoxidation by P450 enzymes. 
1.3.3 Aromatic oxidation 
The aromaticity and high dissociation energy of the C-H bonds of benzene (111 kcal/mol) 
impede its abstraction by P450 enzymes, in contrast to the aliphatic alkanes60, 61. The first 
pathway for hydroxylation of benzene was reported by Jerina et al. in 1969 and involves an 
arene oxide intermediate followed by a hydrogen migration in the aromatic system and phenol 
formation62. This hydrogen migration was reported by the National Institutes of Health and is 
subsequently known as the NIH shift62. The oxidation reaction with P450 enzymes proceeds 
via the addition of iron (IV)-oxyl to the benzene ring (Figure 1. 9)63. Epoxidation after iron 
(IV)-oxyl addition to the ring could proceed by two pathways, one includes a radical formation 
(Figure 1. 9), while the other is derived via a cationic state64, 65 (Figure 1. 9). The formation of 





calculations show that the cationic and radical intermediates could also be generated 
independently63,66. Both pathways generate a phenol product. The radical complex generates 
the epoxide before an NIH shift (Figure 1. 9) and is followed by a tautomerisation to form the 
phenol. In the cationic pathway, the direct proton transfer to the oxygen (Figure 1. 9 b) results 
in the formation of phenol.  
 
Figure 1. 9 Hypothesised mechanism of aromatic oxidation by P450 enzymes. a) the radical 
pathway followed by an NIH shift and tautomerisation; b) direct proton transfer in the cation 
mechanism, which generates phenol. 
1.3.4 Sulfoxidation 
The mutation of threonine, which is essential for molecular oxygen activation and proton 
delivery (see 1.7 Hydrogen peroxide dependent variants) decrease the rate of the hydroxylation 
reaction because of a reduction in the formation of Compound I. However, the sulfoxidation 
rate increases67. This indicates that there could be another oxidant besides Compound I for 
sulfoxidation67. Sulfoxidation is hypothesised to proceed via a concerted mechanism that 
includes the nucleophilic attack of the sulphur on the oxygen of distal H2O2 (Figure 1. 10), 






It has been shown that the cleavage of O-O is the rate determine step, which could be heterolytic 
or homolytic. The comparison of heterolytic and homolytic cleavage showed that the former 
pathway is more energetically favoured67. 
 
Figure 1. 10 The concerted mechanism of sulfoxidation via FeIII (H2O2) oxidant. 
1.3.5 Dehydrogenation 
P450 enzymes can function as oxidase-dehydrogenases and catalyse the desaturation of 
saturated hydrocarbons to unsaturated hydrocarbons (Figure 1. 11). The first step is similar to 
the hydroxylation mechanism, with an initial hydrogen abstraction by Compound I yielding a 
carbon radical35. At this point, the mechanism can branch: either a second hydrogen abstraction 
forms the unsaturated product (Figure 1. 11 bottom) or a single electron transfer from the 
radical to the iron yields a carbocation, followed by proton transfer to generate the unsaturated 






Figure 1. 11 The proposed mechanisms of desaturation of hydrocarbons by P450 enzymes. 
Hydrogen abstraction and oxygen rebound in Fe species followed by; single electron transfer 
(top) or a second hydrogen abstraction (bottom).  
1.4 CYP102A1/ P450Bm3 
CYP102A1 was discovered by Fulco in 1970s71. This protein is the third enzyme isolated from 
Bacillus megaterium, which gave rise to its name, P450Bm371-74. This enzyme is the P450 most 
commonly utilised for chemical reactions because of its self-sufficient nature. This 119 kDa 
monooxygenase is a holoenzyme consisting of a 55 kDa haem domain covalently connected to 
a 65 kDa reductase domain, which contains FAD and FMN flavin groups (1.2 Catalytic cycle 
of P450 ); therefore, it only requires NADPH (as a source of electrons) and molecular oxygen 
to initiate monooxygenase reactions75-77. The significance of the covalent linkage of these 
domains was demonstrated in experiments, where individual expression of the haem and the 
reductase domains showed little affinity for one another77-80. P450Bm3 is a dimer in solution, 
and its catalytic activity arises from its dimeric form30. Studies by Munro et al. showed that at 
low concentrations, P450Bm3 exhibits less activity because of the prevalence of the 
monomeric form31. 
A wide variety of fatty acids have been reported as substrates for P450Bm3, and it was found 





binding and activity. The oxidation of these fatty acids by P450Bm3 takes place at the ω-n (n= 
1-3) positions in different ratios depending on the orientation in the active site (Figure 1. 12)75, 
81-83.  
 
Figure 1. 12 Oxidation of fatty acids by P450Bm3 is regioselective and occurs at the ω-n (n=1-
3) positions. 
Proteolysis of the reductase domain yields two sub-domains, an FAD/ NADPH and an FMN 
region84, 85, and neither is active in the absence of the other86. The formation of semiquinone 
intermediates from the flavins provides a single electron to the haem before oxidising the 
substrate. In microsomal cytochrome P450 reductase (CPR), electrons are transferred from 
NADPH to FAD and then to FMN to form FMNH2. These electrons are shuttled from FMNH2 
to the haem to yield the FMNH semiquinone and the reduced haem intermediate. The electron 
transfer mechanism in P450Bm3 is similar to that of mammalian CPR, although in P450Bm3 
the electrons are shuttled from FMNH instead of FMNH2 (Figure 1. 13), which illustrating the 
difference in reduction potential of CPR and P450Bm387-89. It is thought that the different 
preferences for electron transfer partners are a result of changes in the FMN binding loop of 






Figure 1. 13 A schematic representation of electron transfer in P450Bm3. The electron from 
NADPH forms FAD hydroquinone and transfers to FMN to form FMNH. The electron from 
FMNH is transferred to the domain of P450Bm3 to hydroxylase the substrate90.  
The addition of NADH or NADPH without the presence of substrate inhibits the oxidation 
activity of the P450Bm375, 81. Experimental evidence has also shown that in the absence of 
substrate, the enzyme loses 70 % of its activity two minutes after addition of NADPH and after 
ninety minutes only 10 % of activity remained. Inactivation of the enzyme was determined to 
arise from a change in the reductase domain, as incubation of the haem domain with NADPH 
does not hamper the activity of the enzyme91-93.  
1.5 Key Residues in P450Bm3 
Similar to the some of the mammalian P450s, P450Bm3 crystallises in an open conformation 
(PDB 1BU7)94. In this precatalytic conformation, the substrate is not close enough to the haem 
centre and therefore, there is no accurate structural data of a catalytically relevant form of the 
enzyme86. However, the available crystal structure does enable some of the key requirement of 
fatty acid oxidation to be elucidated. Based on the oxidation of fatty acids by P450Bm3, Fulco 
et al. presumed the presence of a hydrophilic region near the haem centre, and this hypothesis 





The carboxyl group of palmitoleic acid interacts with Arg47 and Tyr51, two polar residues in 
the entrance of the active site (Figure 1. 14). The mutation introduced at these two positions96, 
97, decreases the affinity of the enzyme for fatty acids. A double mutation of R47A/Y51F 
showed only one-third activity of the WT enzyme towards oxidation of fatty acids. Hence, 
Arg47 and Tyr51 are known as gatekeepers of P450Bm398. Arg47 does not bond to the 
substrates and Tyr51 harness the substrate by forming a hydrogen bond to the fatty acid 
substrates99, 100 (Figure 1. 14). 
The selectivity of P450Bm3 for sub-terminal positions of the substrate can be partly attributed 
to the Phe87 residue. This phenylalanine is close to the haem centre and in the absence of 
substrate settles perpendicular to the haem106 90 (Figure 1. 14). Upon substrate binding, the 
Phe87 residue rotates 90° and is placed between the haem and tail of the substrate and help to 
orient the aliphatic chain hydroxylation, which leads to sub-terminal hydroxylation104. It was 
found that the flexibility of the substrate assists the enzyme in increasing the activity towards 
its sub-terminal tail, which is closer to the haem moiety. Therefore, Phe87 may be more 
effective at catalysing hydroxylation at the sub-terminal position, but it is not the only driving 
force for regioselectivity86. Mutagenesis of Phe87 to smaller amino acids made the access 
channel larger and enabled the enzyme to oxidise bulkier substrates, e.g. naphthalene and 
indole86. F87V and F87A are examples of Phe87 mutations which are commonly employed as 






Figure 1. 14 Location of key residues in WT P450Bm3 in the presence of the N-palmitoyl 
glycine (yellow). The mesh area shows the active site of the enzyme (PDB: 1JPZ)101.  
An acid-alcohol pair is conserved in most P450s, which facilitates oxygen activation. In many 
P450s, these acid-alcohol pair are aspartic acid (Asp)-threonine (Thr) or glutamic acid (Glu)-
Thr. The alcohol residue has an essential role by stabilising the water molecules close to the 
coordinated dioxygen via hydrogen bonding102. In P450Bm3, the glutamic acid and threonine 
residues are at positions 267 and 268 respectively107. The mutation of glutamic acid to 
glutamine decreased the activity of the WT enzyme to only 5 % with palmitic acid as the 
substrate103. The side chain of Glu267 is hydrogen bonded to a water molecule in the active 
site of the substrate-free crystal structures, and mutations to non-polar residues would disrupt 
proton delivery.  
The polar nature of Thr268 enables this highly conserved residue to also contribute to proton 
delivery, activation of dioxygen and subsequently the stabilisation of the oxy-ferrous or ferric-
hydroperoxy intermediates104, 105. The T268A mutation had an adverse effect on the oxidation 
of palmitic, arachidonic and lauric acids119,106, which showed the significance of the threonine 
side-chain for hydrogen bonding to the water molecule near the active site in the WT enzyme 





evidence that the water molecule is stabilised by the Thr268 residue107. However, De Voss et 
al. have shown the T268A mutant is functional with myristic acid, which may indicate that 
specific substrates can circumvent this requirement108. Recently the introduction of a glutamic 
acid mutation at the Thr268 position converted P450Bm3 into an H2O2-dependent variant (see 
1.7 Hydrogen peroxide dependent variants)104.  
1.6 Mutagenesis and biocatalytic applications of P450Bm3 
Enzymatic reactions have emerged as promising alternatives to chemical oxidation in organic 
synthesis. These biocatalytic enzyme reactions occur under mild conditions109-111 and in 
contrast to the chemical catalysts, are environmentally benign. P450 enzymes have been of 
interest because of their ability to selectively hydroxylate unreactive C-H bonds at ambient 
pressure and temperature111. Moreover, enzymes can be generated in a soluble form using 
Escherichia coli and readily purified in high yields112-114.  
The high catalytic activity of P450Bm3 has made it the most utilised enzyme of this 
superfamily for biocatalysis115-117. The highest kcat  (285 s
-1) was reported for the oxidation of 
arachidonic acid with WT P450Bm396. However, the WT enzyme is more selective for its 
natural substrates, given that the key residues around the active site hamper the entrance of 
non-native substrates. Enzyme engineering, by introducing direct and random mutations, has 
increased the substrate range of P450Bm383, 118-121. For example, no activity was observed for 
P450Bm3 towards the oxidation of alkanes before Farinas et al. reported an evolved variant of 






Figure 1. 15 Crystal structure of WT P450Bm3 in the presence of the N-palmitoyl glycine 
(blue). Shown are residues (yellow) around the active site (grey mesh) (PDB: 1JPZ)101.  
Mutation of key residues, such as Arg47 and Tyr51, also changed the preference of the enzyme 
towards different substrates. The R47L/Y51F variant has been used to catalyse the oxidation 
of more hydrophobic substrates like polycyclic aromatic hydrocarbons122. Isoleucine at 
position 401(I401P) is beneath the haem in the active site (Figure 1. 15), and it has shown that 
mutation of Ile401 to Pro changes the conformation of the enzyme and places it in an active 
state. The I401P and I401M mutations were proposed to make P450Bm3 more capable of 
binding hydrophobic substrates and as a consequence, the oxidation rate increased101, 119.  
The KT2 (A191T/N239H/I259V/A276T/L353I) variant has also been reported to increase the 
oxidation rate of P450Bm3 because of a more catalytically active conformation (Figure 1. 
16)123, 124. KT2 was developed by random mutation; and it is of note that the mutations are not 
in the active site. In the WT enzyme, there are two salt bridges (Lys224-Asp251 and Asp212-
Arg255) which link the I and G helices. The mutations in KT2 disrupt these bridges, leading 
to breakage of several hydrogen bonds in the structure and a conformational change124. The 





ligand is no longer hydrogen bonded to Ala264 which better assists the triggering of the 
catalytic cycle. The alteration in conformation and enzyme structure make KT2, like I401P, a 
catalytically ready variant (Figure 1. 16)124. Other variants of P450Bm3 contain mutations in 
and around the active site enable it to become a biocatalyst for the oxidation of arenes92, 
steroids125-128, terpenoids129, 130 alkanes92, 131, 132 and other substrates. 
 
Figure 1. 16 Crystal structure overlays of substrate-free (SF) KT2 (yellow, with waters as red 
spheres and hydrogen bonds as red dashed lines), SF WT (grey, waters as dark blue spheres 
and hydrogen bonds in black) and NPG-bound WT (green, waters as green spheres and 
hydrogen bonds in blue). A) the Lys224-Asp251 bridge is broken in KT2: B) SF KT2 adopts 
the same catalytically active conformation of  NPG-bound WT. C) The structure of the active 
site within SF WT differs from the NPG-bound WT. D) The overlay of the active site of NPG-
bound WT and SF KT2, showing closely matched structures (PDB 3PSX). This figure is from 
“Structure, electronic properties and catalytic behaviour of an activity-enhancing CYP102A1 





1.7 Hydrogen peroxide dependent variants 
Cytochrome P450 enzymes are monooxygenases because they used molecular oxygen in the 
presence of NADH or NADPH to produce the active oxidant Compound I. In 1994, Matsunaga 
et al. first reported that CYP152B1 from Sphingomonas paucimobilis (P450SPα) oxidises fatty 
acids using H2O2
133 and the first crystal structure of the related CYP152A1 (P450BSβ) from 
Bacillus subtilis was reported by Lee et al. in 200312. Both P450BSβ and P450SPα lack the 
acid-alcohol pair of residues, which facilitate oxygen activation for the Compound I 
formation134-137 (1.5 Key Residues in P450Bm3). In P450BSβ, instead of the acid-alcohol 
residues, the interaction between the carboxylic group of the substrate and guanidine group of 
Arg242 (Figure 1. 17) assists the activation of the enzyme by formation of Compound I in the 
presence of the H2O2 (Figure 1. 18)
138. 
 
Figure 1. 17 The palmitic acid-bound P450BSβ shows the interaction (red dashed line) 
between Arg242 (green) and carboxylic group of the palmitic acid (blue) in the active site (grey 
mesh) (PDB: 1IZO)138.  
The subsequent crystal structure of P450SPα by Fujishiro et al. confirmed the importance of 





activation of the enzyme139. A recent study by Onada et al. reported the oxidation of non-native 
substrates of P450SPα and P450BSβ by employing short chain length n-alkyl carboxylic acids 
as decoy molecules140. The carboxylic group of the decoys binds to the glutamic acid in Arg242 
(P450BSβ) or Arg241 (P450SPα), in the presence of H2O2, allowing the formation of 
Compound I and this enables the oxidation of non-native substrates (Figure 1. 18). Shoji et al. 
reported that the mutation of Ala245 to glutamic acid placed a carboxylate group close to the 
haem moiety and increased the formation of Compound I for non-native substrates and hence 
allowed their oxidation141. The location of Ala245 corresponds to the alcohol Thr268 in 
P450Bm3. Therefore introducing a single mutation of T268E in P450Bm3 provide a 
carboxylate group at position 268 and Arg241, which is essential for the formation of 
Compound I (Figure 1. 18), and allows P450Bm3 to be driven by hydrogen peroxide141. 
Therefore, instead of following molecular oxygen-driven the catalytic cycle of normal P450s 
with activation of Compound I, the H2O2 dependent P450Bm3 hydroxylates substrates via the 
H2O2 shunt pathway (Figure 1. 18). Considering the high expense in using NADPH, converting 
P450Bm3 to a H2O2 dependent variant benefits the industrial application of the enzyme. 
 
 





1.8 Decoy molecules 
Enzyme engineering has been carried out on P450Bm3 to enable the oxidation of an extensive 
range of non-native substrates (1.6 Mutagenesis and biocatalytic applications of P450Bm3). 
Decoy molecules have also been employed to exploit the activity of P450Bm3 further. 
Kawakami et al. in 2011 first reported the application of decoy molecules in the oxidation of 
gaseous alkanes by P450Bm3142. Given fatty acids with 12-15 atom-long chains are the optimal 
substrates for P450Bm3, polyfluorinated fatty acids (PFCs) were initially chosen as decoy 
molecules for P450Bm3. The carboxylic group in PFCs (Figure 1. 19) will be tethered by 
Arg47 and Tyr51 (Figure 1. 20) enabling the enzyme to transfer into a more catalytically ready 
conformation143-146. However the strong C-F bonds, cannot be oxidised by P450Bm3147 
Compared to natural substrates, decoy molecules are designed to have a shorter length chain, 
leaving a cavity in the active site and therefore non-native substrates have access to space above 
the haem iron. The most commonly employed PFCs with P450Bm3 are polyfluorinated fatty 
acids with 8 to 10 chain length (PFC 8-10), and their dissociation constants have been reported 
Kd = 1900, 980 and 290 μM, respectively. The shorter PFCs have a lower resemblance to 
natural substrates, therefore their binding affinity for the active site of P450Bm3 decreases and 
makes them less effective decoy molecules147, 148. Using decoy molecules enables 
hydroxylation of a variety of substrates by WT P450Bm3. However, the catalytic activity is 
often lower than with the natural substrates, since these decoy molecules do not fully interact 






Figure 1. 19 Structures of decoy substrates designed for P450Bm3. At the top, the first 
generation decoy molecules are shown, and the bottom shows the second generation decoy 
molecules, which employ an amino acid head in place of the normal fatty acid carboxylate head 
(green box). 
It was reported that WT P450Bm3 shows higher oxidation activity for N-palmitoyl glycine 
than palmitic acid because of the lower dissociation constant of the former148. The Gln73 and 
Ala74 residues form hydrogen bonds to the carboxylate group of N-palmitoyl glycine and 
increase the binding affinity107. This finding led to the proposal of “second generation” decoy 
molecules; these include an amino acid head, which would enhance activity more than the first 
generation148 (Figure 1. 19). These amino acid-based decoys were observed to bind more 






Figure 1. 20 The crystal structure of P450Bm3 with a bound PFC-9-L-Trp decoy molecule 
(orange). The key and hydrophobic residues (yellow) around the active site (grey mesh) are 
shown (PDB: 3WSP). 
1.9. Immobilisation of P450Bm3 
1.9.1 Zeolitic imidazolate frameworks (ZIFs)  
P450 enzymes are potential biocatalyst for oxidation reactions, but one problem with the 
application of P450Bm3 and other enzymes in chemical synthesis is their low stability towards 
strong oxidative conditions. Furthermore, because of the high solubility of free enzymes in 
aqueous media, separation of the enzyme from the final product is difficult. Enzyme 
immobilisation is one approach that could address these issues and would enable the creation 
of a reusable heterogeneous biocatalyst. Immobilisation would also enable applications of the 
enzyme under more extreme reaction conditions, such as high pH and temperature as well as 





The first example of enzyme immobilisation was reported by Nelson and Griffin in 1916 using- 
physical adsorption of invertase (β-D-fructofuranosidase) on charcoal152. The first industrial 
application of immobilised enzymes was reported by Tanabe Seiyaku in 1969, where an 
aminoacylase was physically adsorbed on DEAE-Sephadex media153.  
Immobilisation methods are classified into four categories: 1) crosslinking; 2) enzyme 
entrapment; (encapsulation) 3) physical adsorption; and 4) covalent binding to a presynthesised 
support154-158 (Figure 1. 21). The efficiency and efficacy of enzyme immobilisation depend on 
the desired application, the properties of the support and the nature of the enzyme158. Various 
supports have been reported for the covalent binding of the enzyme, such as nano-porous silica, 
sepharose, alumina and metal-organic frameworks (MOFs)149, 150, 159, 160. 
 
Figure 1. 21 Different methods of immobilisation include: adsorption, covalent bonding, cross-
linking and encapsulation. 
MOFs are emerging carriers for enzyme immobilisation157, 161. These porous crystals are 
constructed from metal ions and organic ligands in a regular lattice. The various combinations 
of ligands and metal ions can provide an extensive range of MOFs with useful properties, such 
as high porosity and large surface area156, 162, 163. MOFs also offer high thermal (250 ° to 500 
°C) and chemical stability. Zeolitic imidazolate frameworks (ZIFs) are the first example of 
MOFs with useful chemical stability164-166. ZIFs are a subclass of MOFs constructed from 





zeolites167. The chemical environment of a MOF is tuneable, and careful choice of the organic 
ligand with a proper functional group can allow strong interaction between MOF and the 
desired enzyme168.  
The functionality and morphology of MOFs can be modified169-175. For example, in isoreticular 
structures, longer ligands are utilised to increase void space and thus increase the porosity of 
the resulting MOF materials166. Studies by Farha et al. demonstrated that replacing the phenyl 
groups in ligands with less bulky alkyne ones can further increase the surface areas and porosity 
of the crystals176 (Figure 1. 22). 
 
Figure 1. 22 Ligands designed for MOF formation. Replacing the phenyl linkers with alkynes 
was found to increase the area and porosity of crystals. This figure is from “Metal–organic 
framework materials with ultrahigh surface areas: is the sky the limit?” by Farha et al.176.  
These unique features of MOFs make them favourable for a wide range of applications 
including drug delivery177, gas storage, and separation178-180, catalysis181 and energy 
conversion182. The application of MOFs as a support for enzyme immobilisation has been 
studied extensively. Balkus et al. reported the first example of enzyme immobilisation using 
MOFs in 2016. The Microperoxidase-11 (M-11) enzyme, was able to surface adsorbed onto a 





of enzyme immobilisation strategies: 1) diffusion of the enzyme into the pores; 2) surface 
attachment; 3) covalent binding to the surface; and 4) in situ encapsulation175, 183. 
The high porosity of MOFs provides an opportunity for diffusion of enzymes with a smaller 
size than the pores. The earliest enzyme diffusion into the cavity pores was reported for MP-
11 immobilisation in (Tb-mesoMOF) ([Tb16(tatb)16], tatb = triazine-1,3,5-tribenzoate). The 
size of MP-11 is about 3.3 × 1.7 × 1.1 nm184, and diffuses in 3.9 and 4.7 (diameter) cages in 
Tb-mesoMOF. The immobilised MP-11 on Tb-mesoMOF showed higher activity than the free 
enzyme185.  
 
Figure 1. 23 The smaller size of the MP-11 than the cages in Tb-meso MOF, enable its 
diffusion.  a) The crystal structure of MP-11 (PDB: 1OCD); and different cage sizes in Tb-
meso MOF b) 3.9 nm diameter and c) 4.7 nm diameter cages. This figure is from 
“Immobilisation of MP-11 into a Mesoporous Metal–Organic Framework, MP-
11@mesoMOF: A New Platform for Enzymatic Catalysis” by Lykourinou et al.185. 
Another example is the diffusion of cutinase (3 nm length) in NU-1000, which has 3.1 nm 
hexagonal channels and 1.5 nm edge length triangular channels186. Although the high porosity 
of MOFs allows the diffusion of proteins, sometimes the target is larger than the pore size. In 





alternatives of immobilisation is to attach the protein to the surface of the MOF through weak 
interactions, such as hydrogen bonding or hydrophobic interactions. For this purpose, the MOF 
crystals can be synthesised in advance183. In 2006, Balkus et al. reported the first example of 
surface immobilisation of the enzyme on MOFs. The authors immobilised M-11 on a Cu-MOF 
[Cu(OOC-C6H4-C6H4-COO)
1/2 C6H12N2]n. In their procedure, the pre-synthesised Cu-MOF 
was mixed with M-11 for physical attachment; no modification was required161. The 
immobilised M-11 showed a 65 % conversion of the substrate to product161. Liu et al. 
immobilised Bacillus subtilis lipase (BSL2) on HKUST-1 using a similar method ([Cu3(btc)2], 
btc: 1,3,5-benzenetricarboxylate). The performance of the enzyme/MOF composites increased 
17-fold187 compared to the free enzyme. Similar to surface attachment methods, covalent 
binding strategies require the support materials to be synthesised in advance. However, they 
must be designed or post-synthetically modified to enable covalent bonding to the enzyme in 
a specific manner. The chemical bond formed between the amine groups of the enzyme and 
carboxylate groups of the MOF (or vice versa) results in a further increase in the robustness 
and recyclability of the enzyme/MOF compared to non-covalent surface adsorption. The 
pioneering work highlighting covalent binding was reported by Park et al. in 2011 for the 
immobilisation of Candida antarctica Lipase B (CAL-B) on 1D-MOF ([(Et2NH2)(In(pda)2)], 
pda: 1,4-phenylenediacetate), 2D-MOF ([Zn(bpydc)], bpydc: 2,2′-bipyridine 5,5′-
dicarboxylate), and IRMOF-3 ([Zn4O(NH2-bdc)3]) NH2-bdc: 2-amino-1,4-benzene 
dicarboxylic acid. The immobilised enzyme showed higher activity than free CAL-B while its 
enantioselectivity was maintained. CAL-B on IRMOF-3 showed the highest performance with 
a 1000-fold increase compared to the free enzyme188. 
Recently, the potential for in situ encapsulation of an enzyme within a framework has attracted 
much interest189. In this approach, the MOF crystals are directly synthesised around the protein, 





MOF should be synthesised at ambient temperature (or lower) to avoid deactivation of the 
enzyme. Embedding the enzyme into the MOF crystals provides a protective layer around the 
enzyme and prevents leaching of the enzyme back into solution. The first encapsulation was 
reported for cytochrome c (Cyt c)@ZIF-8 by Lyu et al.189. The small pore size of ZIF-8 (3.4 
Å) prevents the diffusion of enzymes into its pores but in situ encapsulation overcomes this 
bottleneck by growing the MOF framework around the enzyme. By the addition of a solution 
of Cyt c and polyvinylpyrrolidone (PVP) to a methanol solution of 2-methylimidazole and zinc 
nitrate hexahydrate, the ZIF-8 crystal grew around Cyt c. Enzyme immobilisation often leads 
to loss of activity, but within ZIF-8, the performance of Cyt c@ZIF-8 improved 10-fold 
compared to the free enzyme. Additionally, the substrate affinity of Cyt c@ZIF-8 was 
increased, which may be attributed to the conformational changes of the enzyme in a methanol 
solution. Alternatively, the microenvironment of ZIF-8 may have improved its substrate 
affinity through a set of interactions in the MOF interior189. 
ZIFs have been of much interest because of their high thermal and chemical stability, high 
porosity, low cytotoxicity, tuneable surface and ease of synthesis under mild conditions165, 190-
192. The first ZIF-8 synthesis was reported in dimethylformamide (DMF) by Chen et al.193. 
Different methods have been reported for synthesising ZIFs, namely; sonochemical protocols 
194, microwave-assisted solvothermal method195, mechanochemical grinding196, 
solvothermal165, 197 and hydrothermal methods198, 199. Furthermore, the molar ratio between the 
ligand and Zn2+ ions can change the resulting crystal size of ZIF-8. For example, the average 
crystal size of ZIF-8 decreased upon increasing the ratio of 2-methylimidazole (HMIM) to Zn 







Figure 1. 24 The scanning electron microscopy of ZIF-8 crystals shows the effect of the 
different molar ratio of HMIM to Zn. The molar ratios are: (a) 40, (b) 60, (c) 80, and (d) 100. 
This figure is from “Formation of high crystalline ZIF-8 in an aqueous solution” by Kida et 
al.199. 
Cui et al. studied show different ratios of Zn:L (1:1 to 1:20) affected the morphology200. Lai et 
al. showed that changing the solvent from DMF to water decreased the micropore volume from 
0.663 to 0.32 cm3 g-1 165, 198, 199. A study by Polyzoidis et al. demonstrated how the reaction 
conditions affected the microscopic and macroscopic morphology of ZIF-8201. In this study, a 
longer reaction time (aging) gave rise to larger crystals, with well-shaped rhombic 
dodecahedral crystals being formed at lower concentrations of reactants. This was rationalised 
by an increase in concentration, leading to an increase in the number of collisions, resulting in 
non-uniform crystals201. ZIF-8 crystals are very stable in alkaline solutions165. However, 
studies from Wang et al. showed that ZIF-8 was decomposed in acidic media202. Such 
properties make ZIFs ideal candidates in drug delivery since at lower pH in the body the 





ZIFs are excellent candidates for in situ encapsulation of an enzyme. They have high chemical 
and thermal stability, in addition to which, they form in aqueous media under mild temperature 
and pH conditions189. When the activity of immobilised horseradish peroxidase (HRP) in ZIF-
8 was investigated by immersing in boiling water for one hour, the free enzyme lost all its 
activity while HRP@ZIF-8 remained 88 % of its activity. This high stability was explained by 
the small pore size of ZIF-8 which fitted tightly around the enzyme. This study compared 
encapsulation of HRP in different pore sized of SiO2 crystals, and it was observed that different 
pore sizes showed a different level of activity205. The smaller pore size in SiO2, the higher 
activity maintained by HRP. For example, HRP@SiO2 with 7 nm pore showed 65 % activity, 
while this value for 100 nm sized pores in SiO2 was only 13 %
205. Liang et al. synthesised ZIF-
8 at a 1:4 molecular ratio of Zn to ligands for encapsulation of bovine serum albumin (BSA) 
and showed that by increasing the concentration of BSA the formation rate of the BSA/ZIF-8 
biocomposite was enhanced, while its crystallinity decreased205. 
Additionally, it was shown that the presence and concentration of the protein affect the 
formation of ZIF-8 and may require a higher ratio of ligand to zinc205-207. A study by Pitzalis 
et al. showed that by decreasing the pH of the synthetic solution, the loading of the enzyme 
increases208. They also reported that the highest surface area for ZIF-8 was obtained at pH 10.2, 
and at pH 9.4, the surface area decreased208.  
Other types of ZIFs have been successfully employed for encapsulation. Shieh et al. reported 
the encapsulation of catalase within a ZIF-90 framework. One of the good examples of 
immobilisation is its application in the textile industry. Catalases and proteases are both 
employed in the textile industry. Proteases cleave the peptide bonds of the catalase; therefore, 
their coexistence in solution is prohibited. To protect catalase in the presence of the proteases, 





an aqueous solution of zinc nitrate, Zn (NO3)2, was added to an aqueous solution of 
imidazolate-2-carboxaldehyde (HICA), catalase, and PVP as the stabilising agent. The smaller 
pore size of ZIF-90 than catalase prevents the leaching of the encapsulated enzyme and 
protecting it against protease. Overall the high chemical stability of ZIF-90 combined with its 
synthesis in water and size control makes it favourable support for in-situ encapsulation209-211. 
1.9.2 Bacterial compartments 
Compartmentalisation is a strategy where cells use protein compartments to store nutrients and 
control metabolism212, 213. The protein-based compartments have been employed in various 
technologies, for example imaging probes214, delivery systems215 and nanoreactors216. For 
example, icosahedral viruses have been employed in the encapsulation of chemotherapeutic 
agents, allowing for a controlled released of medicine217. The encapsulation of biomolecular 
cargo can be performed by interior modification of protein for electrostatic, hydrophobic and 
hydrogen bonding interaction between cargo and protein218-220. Cowpea Chlorotic Mottle virus 
(CCMV) has been used for encapsulation by adjusting the pH. The virus solution dissociates 
at pH 7.5 into 90 dimers and forms capsids at pH 5.0. Cargo can be added to the CCMV at pH 
7.5, and subsequent lowering of the pH to 5.0 promotes capsid formation (Figure 1. 25). Since 
CCMV has an interior positive charge, it favours negatively charged cargo molecules218, 221-223.  
Bacterial micro compartments (BMCs) are a family of organelles formed by 4-7 individual 
shell proteins, with approximately 4000 subunits yielding an icosahedral geometry with an 80-
400 nm diameter224 225. The first study showing the possibilities of BMCs for cellular inclusion 
was in 1961 when dense polyhedron-shaped carboxysomes were discovered by electron 







Figure 1. 25 Schematic encapsulation of enhanced green fluorescent protein (EGFP) in CCMV 
virus. The tagged EGFP is mixed with capsid at pH 7.5 and dialyzed to pH 5.0. This figure is 
from “Controlled Encapsulation of Multiple Proteins in Virus Capsids” by Minten et al.218. 
The efficient growth of a group of microorganisms under inorganic carbon-limiting conditions 
was attributed to the encapsulation of Rubisco (RuBisCO) and carbonic anhydrase in the 
carboxysome. This assisted the microbe to grow by allowing it to fix carbon dioxide via a 
carbon concentrating-mechanism229, 230. It also was suggested that the carboxysomal shell 
prevents oxygen from reaching the enzyme inside. As RuBisCO is a bifunctional enzyme that 
catalyses fixation of O2
231, 232 and blocking an increase in oxygen concentration enhances the 
activity of the enzyme233. Subsequently, the structure of these carboxysomes was studied to 
gain insight into the mechanism of outer shell formation. Electron microscopy of the 
carboxysome showed polyhedral bodies with an average diameter of 100 nm in an icosahedral 
structure with 5-, 3- and 2-fold symmetry axes (Figure 1. 26 a)234. 
The crystal structure of the carboxysome showed that the shell is formed by the assembly of 
smaller unit proteins. In Halothiobacillus neapolitanus, the genes responsible for carboxysome 
function are encoded in the Cso operon. These small shell proteins are named carboxysome 





Csos1B. These proteins possess 80 % sequence similarity. CsoS1A is a cyclic hexameric 
building block, consisting of six monomeric subunits with a central pore (Figure 1. 26 b) 235.  
 
 
Figure 1. 26 a) The polyhedral bodies formed by carboxysome, which possesses icosahedral 
symmetry, b) Representation of the hexamer structure of CsoS1A. Figure a is from “Structure 
of Halothiobacillus neapolitanus carboxysomes by cryo-electron tomography” by Schmid et 
al.234. Figure b is from “Structural analysis of CsoS1A and the protein shell of the 
Halothiobacillus neapolitanus carboxysome” by Tsai et al.236. 
A large carboxysome with a diameter of 1,100 Å has 4,500 shell subunits (triangulation 
number1, T= ~75), whereas a small carboxysome shell with a diameter of ~850 Å contains 
~3,500 shell subunits (T= ~60)237. For many years the only known BMCs were carboxysomes, 
until 1994, when it was found that Salmonella enterica could form polyhedral organelles 
involved in coenzyme B12-dependent 1,2-propanediol degradation
238. By packaging the B12-
dependent diol dehydratase and other enzymes responsible for diol degradation in a protein 
shell, the cells could be protected from propionaldehyde, which is a toxic intermediate of diol 
degradation239. Further studies showed that the BMC domains could be found in enteric 
bacteria like Escherichia coli. Also, 189 BMC genes have been identified so far in the 
 





Acidobacteria, Actinobacteria, Planctomycetes, Fusobacteria, Firmicutes and almost all 
groups of the Proteobacteria237.  
Encapsulins are a novel class of BMCs that have been recently characterised240. Encapsulins 
were discovered as high molecular weight aggregates in by Brevibacterium linens in 1994241, 
242. They have a smaller diameter than other BMCs, (25-32 nm), and are known as nano 
compartment proteins242-246. In contrast to viruses like CCMV, which are pH dependent and 
can be reversibly disassembled, reversely at different pH, encapsulins are highly stable. This 
makes encapsulin an attractive target for packaging proteins to stabilise them at higher 
temperatures and extreme pH247, 248. In contrast to BMCs that form from multiple homologous 
proteins, encapsulins are comprised of a single protein249, 250, that can be employed to package 
the cargo protein inside. The cargo protein requires a peptide tag, identical to the native cargo 
encapsulin, on the C terminus region240. This peptide tag acts as an anchor, enabling the 
interaction of non-native cargo proteins with the encapsulin. Two architectures have been 
reported for encapsulins so far. The first group includes Thermotoga maritima (T. maritima)240, 
Rhodococcus erythropolis248 and Mycobacterium tuberculosis244. These have a triangulation 
number =1 (T= 1) and consist of 60 identical subunits with a 20-24 nm diameter. Pyrococcus 
furious250 and Myxococcus xanthus (M. xanthus)250 from the second group, which have a 
triangulation number of three (T= 3), and contained 180 identical subunits with a larger 
diameter (30-32 nm)251. 
Due to their properties and being able to internalize various cargo proteins by simply 
introducing a targeting sequence at the C-terminal, encapsulins are an attractive platform for 





Various strategies to improve the oxidation activity of P450Bm3 will be studied in this thesis. 
To exploit the activity of P450Bm3 in the oxidation of the non-natural substrate, different 
mutuant forms will be investigated. To improve the oxidation activity of P450Bm3, the rate 
accelerating variants (RLYFIP, KT2 and R19) will be studied, and their regio- and 
stereoselectivity will be compared with WT P450Bm3 (chapter 3). The effect of decoy 
molecules in combination with different variants will be evaluated (chapter 4). The mutation 
of phenylalanine in the active site, within the GVQ variant, will be studied to check how it 
alters the activity and selectivity of P450Bm3 (chapter 5). The effect of altering substrate and 
decoy molecule size on the oxidation activity of P450Bm3 variants will also be discussed 
(chapter 5). A potential role for P450Bm3 variants in flavour and fragrance industries will be 
examined in the selective biocatalytic oxidation of isophorone to (R)-4-hydroxyisophorone 
(chapter 6). The mutation of threonine 268, which is involved in dioxygen activation, will be 
investigated to study the changes in the catalytic cycle of P450Bm3. The epoxidation, 
hydroxylation and sulfoxidation activity of this haem domain which uses H2O2 will be 
compared with P450Bm3 holoenzymes. It also will be examined to assess if decoy molecules 
are effective in improving the activity of this variant (chapter 7). To improve the thermal and 
chemical stability of the P450Bm3, its immobilisation in zeolitic imidazolate frameworks (ZIF-







Experimental data for chapter 8 are provided in this chapter. Experimental details for the 
published papers are included in these chapters, either in the main paper or supplementary 
information. 
General 
General reagents and organics were purchased from Sigma-Aldrich, Tokyo Chemical Industry 
(TCI), Chem-Supply or Fluorochem. Isopropyl-β-D-thiogalactopyranoside (IPTG), antibiotics 
and buffer components were obtained from Astral Scientific (Australia). 
UV-Vis spectroscopy assays were performed on an Agilent Cary 60 spectrophotometer and 
were recorded at 30 ± 0.5 ºC. Gas Chromatography-Mass Spectrometry (GC-MS) was carried 
out on a Shimadzu GC-2010 with GC–MS-QP2010S detector with a DB-5 MS fused silica 
column (30 m × 0.25 mm × 0.25 μm). Gas Chromatography (GC) was carried on a Shimadzu 
Nexus GC-2030 with FID detector and a DB-Wax column (30 m × 0.25 mm × 0.25 μm). The 







Table 2. 1 GC-MS and GC operating conditions 
GC-MS 
Helium flow rate 1.3 ml min–1 
Injector temperature: 250 °C 
Interfacer temperature: 280 °C 
Method 
styrene 60 °C (hold 3 min), 10 °C min-1 to 200 °C (hold 5 min) 
isophorone 80 °C (hold 3 min), 10 °C min-1 to 200 °C (hold 5 min) 
GC 
Helium flow rate 3.5 ml min–1 
Injector temperature: 250 °C 
Interfacer temperature: 250 °C 
 
styrene 60 °C (hold 3 min), 6 °C min-1 to 120 °C (hold 2 min), 25 °C  
min-1 to 220 °C (hold 2 min) 
isophorone 100 °C (hold 3 min), 8 °C min-1 to 180 °C (hold 6 min.), 25 °C 
min-1 to 220 °C (hold 2 min.) 
 
2.1 Protein expression and purification 
The plasmid pT7 containing the gene encoding the P450Bm3 haem domain Thr268Glu mutant 
(Bm3TE) was transformed into E. coli BL21 (DE3) competent cells and grown on an LB plate 
in the presence of ampicillin (100 μg ml-1). A single colony was added to 500 mL of LB2 media 
containing trace elements solution (CaCl2, ZnSO4.7H2O, MnSO4.H2O, Na2-EDTA, 
FeCl3.6H2O, CuSO4.5H2O, and CoCl2.6H2O) and ampicillin, was incubated at 37 °C, 110 g. 
After 14 hours incubation, the temperature was lowered to 18 °C followed by the addition of 
0.02 % v/v benzyl alcohol and 2 % v/v ethanol after 30 min. IPTG (100 μM) was added to 
induce protein expression. Cells were harvested after 24 hours by centrifugation (5000 g, 10 
min, 4 °C) and resuspended in Tris buffer (50 mM, pH 7.4, containing 1 mM DTT). The cells 
were lysed by sonication on ice for 30 min (20 s on, 40 s off) and cell debris was removed by 
centrifugation (40000 g, 20 min, 4 °C). The supernatant was loaded onto a DEAE Sepharose 
column (XK50, 200 mm × 40 mm; GE Healthcare) and eluted using a linear salt gradient (100- 
400 mM KCl in Tris buffer). The red coloured fractions which contain the P450 enzyme were 
 




combined and concentrated by ultrafiltration (1900 g, 4 °C) using 10 kDa membranes (Vivacell 
100, Sartorius). Concentrated protein was desalted using a Sephadex G-25 medium grain 
column (250 mm × 40 mm; GE Healthcare). This was concentrated by ultrafiltration as 
described above to approximately 10 ml before being loaded onto a Source-Q ion-exchange 
column (XK26, 80 mm × 30 mm, GE Healthcare). The proteins were purified on an AKTA 
purifier (GE Healthcare) and eluted using a linear salt gradient (100 - 400 mM KCl in Tris 
buffer). Fractions with A418/A280 > 0.5 were collected and concentrated. Afterwards, an 
equivalent volume of 80 % glycerol was added to protein and filter sterilised before it was 
stored at -20 °C. 
2.2 Spin state shift 
Bm3TE was diluted to ~ 3 μM with Tris buffer (50 mM, pH 7.4). An aliquot of the 2-
methylimidazole (HMIM) (0.5 μL from 160 mM stock solution in ethanol) was added to 500 
μL of the enzyme solution, and the spectrum was recorded from 700 nm to 250 nm. Further 
aliquots of the substrate were added until the enzyme solution was saturated with the substrate. 
2.3 Encapsulation of Bm3TE@ZIF-8 
Bm3TE (1 ml) in Milli-Q H2O was added to 500 μl of an aqueous solution of 2-
methylimidazole (HMIM, 640 mM) and mixed with 500 μl of an aqueous solution of zinc 
acetate dihydrate (Zn(CH3CO2)2.2H2O, 40mM). The molar ratio of HMIM:Zn was held at 16:1. 
The solution was aged at room temperature under the static condition for 24 h. The resultant 
white crystalline powder was collected by centrifugation (7000 g, 5 min) and then washed, 




2.4 Encapsulation of Bm3TE@ZIF-90 
Bm3TE (1 ml) in Milli-Q H2O was added to 500 μl of an aqueous solution of 2-imidazole 
carboxaldehyde (HICA, dissolved at elevated temperature, 160 mM) and mixed with 500 μl of 
an aqueous solution of zinc nitrate hexahydrate (Zn(NO3)2·6H2O, 40 mM). The molar ratio of 
HICA:Zn was held at 4:1. The solution was left at room temperature under static conditions for 
4 h. The precipitate was collected by centrifugation (7000 g, 5 min) and then washed, sonicated 
and centrifuged (×3) to remove any loosely adsorbed enzyme.  
2.5 Pre-synthesised ZIF-8 crystals 
Zinc nitrate hexahydrate (Zn(NO2)3·6H2O, 58.8 mg, 0.197 mmol) was dissolved in methanol 
(4 ml). In a separate vial 2-methylimidazole (HMIM, 64.8 mg, 0.787 mmol) was dissolved in 
methanol (4 ml). Both solutions were sonicated until the solids dissolved. The (Zn(NO2)3·6H2O 
solution was added to the solution of HMIM, and the mixture was left at room temperature to 
age under static conditions for 24 hrs. The resultant white suspension was centrifuged (7000 g, 
5 min)  and washed with methanol (5×10 ml) then dried yielding a white crystalline powder253. 
2.6 Pre-synthesised ZIF-90 crystals 
Zinc nitrate (Zn(NO3)2, 37.125 mg) was dissolved in water (2 ml) and added to 2 ml of a 
solution of 2-imidazole carboxaldehyde (HICA, 40.0 mg) in MilliQ H2O/glycerol (9:1-1:1). 
(For PVP studies, 5.0 mg PVP (0.2 wt %,) was added to the solution). The reaction mixture 
was left at room temperature, and the precipitated products were collected by centrifugation 




2.7 Powder X-ray diffraction 
Powder X-ray diffraction (PXRD) data were collected on a Bruker D8 Advance or D4 
Endeavor X-ray powder diffractometer. The details of the PXRD are provided in Table 2. 2. 
The data obtained from the D4 instrument were converted by PowDLL Converter and 
expressed as the Cu source radiations.  
Table 2. 2 PXRD D8 and D4 operation conditions. 
X-ray powder 
diffractometer 
Diffraction method Source of 
radiation 
Kα radiation (Å) 2 θ (°) 
D8 capillary (0.5 mm) loaded Cu anode 1.5418 2-52 
D4 flat plate Co anode 1.78897 5-32 
2.8 Scanning electron microscopy (SEM) 
SEM images were collected using a Philips XL30 Field Emission Scanning Electron 
Microscope (FESEM) at Adelaide Microscopy. Samples were dry loaded onto adhesive tabs 
on aluminium stubs and coated with a 5 nm carbon coating. N2 (UHP grade) adsorption 
isotherm measurements were performed on a 3Flex physisorption analyser. The temperature 
was maintained at 77 K via a helium cryostat253. 
2.9 Fluorescein isothiocyanate-tagged Bm3TE 
Fluorescein isothiocyanate (FITC, 0.5 mg) and Bm3TE were dissolved in carbonate-
bicarbonate aqueous buffer solution (4 mL, 0.1 M, pH 9.2) and left for twelve hours in the dark 
at 4 °C under gentle stirring. The fluorescein-tagged Bm3TE, FITC-Bm3TE, was recovered by 
passing the reaction mixture through an Illustra NAP-25 column (GE Healthcare Life Sciences, 




centrifugation at 4 °C (4000 g for 20 min), followed by solvent-exchange with MilliQ H2O 
twice to ensure the complete removal of buffer salts in the solution. The concentrated tagged 
protein solution was passed again through a NAP-25 column to ensure the complete removal 
of unreacted FITC molecules255. 
2.10 Confocal laser scanning microscopy (CLSM) 
The presence and spatial location of the fluorophore-tagged proteins in (or on) the MOFs 
composites was determined using CLSM (Olympus FV3000 Confocal Laser Scanning 
Microscope, OLYMPUS). The fluorescein-tagged proteins were excited at 488 nm, and the 
fluorescence signal was collected in a window from 495 to 545 nm256.  
2.11 Activity assays 
The peroxygenase turnover assays for the Bm3TE variant was run in 500 μl Tris buffer (pH 
7.4, 50 mM) at room temperature containing 3 μM enzyme and 5 mM of the substrate. The 
reaction was started by the addition of 60 mM H2O2 and quenched after 5 min by the addition 
of 400 μl ethyl acetate.  
The NADPH monooxygenase turnover assays for Bm3R19 was run in 500 μl Tris buffer (pH 
7.4, 50 mM), containing ~200 nM enzyme (Bm3R19 variant was generated as detailed in 
Chapter 7). 1 mM of the substrate and ~ 320 μM NADPH was added. The reaction was mixed 
by inversion and left overnight to ensure it ran to completion. 
After the NADPH consumption or H2O2 assays were completed, 495 μL of the reaction mixture 
was mixed with 5 μL of an internal standard solution (p-cresol, 20 mM stock solution in 
DMSO). The mixture was extracted with 400 μL of ethyl acetate, and the organic extracts were 




experiments and matching the GC-MS spectra to those of the products. Metabolites were 
calibrated against authentic standards using the assumption that isomeric products would give 
comparable responses, e.g., phenylacetaldehyde and styrene oxide were presumed to give the 
same detector response. 
2.12 Encapsulation of Bm3R19 in Mx and Tm encapsulins 
Plasmids of pCDFDuet (Novagen, Merkmillipore) containing the gene encoding the cargo 
plasmid (Bm3TmTP or Bm3MxTP) and pBAD with the encapsulin (TmEnc or MxEnc) genes 
were transformed together into E. coli BL21 (DE3) competent cells, for co-expression, and 
grown on an LB plate in the presence of ampicillin (100 μg ml-1) and streptomycin (50 μg ml-
1). A single colony was added to 5 mL of LB media containing ampicillin and incubated at 37 
°C, 110 g overnight. 500 μl of the overnight culture was added to 50 ml LB and incubated at 
37 °C, 110 g. After 4 hours the temperature was lowered to 18 °C followed by the addition of 
0.02 % v/v benzyl alcohol and 2 % v/v ethanol after another 30 min IPTG (100 μM) was added 
to induce cargo protein expression. Cells were harvested after 3 hours by centrifugation (5000 
g, 7 min, 4 °C). The cell pellet was resuspended in 100 ml fresh LB containing streptomycin 
(50 μg ml-1) and induced with 0.2 % arabinose followed by overnight incubation at 20 °C, 80 
g. The overnight growth was centrifuged at 4600 g for 7 min to harvest the cell pellet. The 
pellet was resuspended in 30 ml Tris buffer (20 mM, pH 8) and sonicated on ice for 10-15 min 
(20 s on, 20 s off, Branson Ultrasonics Sonifier B-30, microtip, 3.2 mm). The cell lysate 
centrifuged at 18000 g for 12 min at 4 °C. The supernatant was collected, and 500 mM NaCl 
was added. Addition of 10 % PEG 8000 turned the solution cloudy, after a gentle mixing the 
solution was left on ice and centrifuged at 38000 g for 12 min at 4 °C after 40 min. The pellet 
was centrifuged again at 38000 g for 5 min at 4 °C, and residual supernatant was removed using 




g for 5 min. The pellet was resuspended in ~13 ml cold Tris buffer (20 mM, pH 8) and filtered 
through 0.2 μm syringe filter. The filtered protein (3 ml) was loaded to HiPrep 16/60 Sepharcyl 
S-500 HR column (GE Healthcare) in Tris buffer (20 mM, pH 8) on AKTA purifier (GE 
Healthcare) and eluted with 1 ml min-1 Tris (20 mM, pH 8). The encapsulin containing fractions 
were collected and concentrated by ultrafiltration (1900 g, 4 °C) using 10 kDa membranes 
(Vivacell 100, Sartorius), then loaded to HiTrap Q FF anion exchange eluted using a linear salt 
gradient (0 - 1 M NaCl in Tris buffer)252. 
2.13 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE was run using 10 % Tris-Glycine gel, staining with Coomassie Blue and ran under 
Tris-Glycine-SDS buffer. Colour Prestained Protein Standard, Broad Range 11 – 245 kDa 
(NEB) was used as a ladder for SDS-PAGE. The Gel matrixes are provided in Table 2. 3 
Table 2. 3 Gel matrix for SDS-PAGE 
 Separating Gel (10 %) Stacking Gel 
H2O  3.8 ml 3.6 ml 
1 M Tris pH 9  7.8 ml - 
1 M Tris pH 7 - 625 μl 
10 % SDS 200 μl 50 μl 
Acrylamide 4.8 ml 800 μl 
10 % APS* 200 μl 50 μl 
TEMED** 20 μl 5 μl 
* APS: Ammonium persulfate 
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Immobilisation of Bm3TE in ZIF-8, ZIF-90 crystals and 
nanobacterial compartments (encapsulins)  
8.1 In situ encapsulation of Bm3TE@ZIF-8 
The lower cost of using H2O2 for oxidation reactions with Bm3T268E (Bm3TE) make this 
variant a promising biocatalyst for oxidation reactions (Chapter 7). However, there are 
drawbacks using free enzymes which hamper their applications for efficient processes. The 
inability to separate the homogenous enzyme from the product and low thermal and chemical 
stability restrict the recycling of enzymes after a reaction, which can lead to an increase in the 
expense257-261. The regio- and stereoselectivity potential of enzymes has led to many studies to 
improve their functional properties like recyclability and higher stability262-264. Zeolitic 
imidazolate frameworks (ZIFs), are suitable candidates for the immobilisation of enzymes 
because they can be synthesised under biologically compatible conditions (1.9.1 Zeolitic 
imidazolate frameworks (ZIFs)). In this chapter, immobilisation of Bm3TE in ZIF-8 and ZIF-
90 crystals and nanobacterial compartments (encapsulin) (1.9.2 Bacterial compartments) is 
studied in an attempt to increase the stability of the enzyme. 
Encapsulation of P450Bm3TE was carried out using a method adapted from the work of Liang 
et al.205. P450Bm3TE in water (high concentration of phosphate buffer in Bm3 purification 
might decompose ZIF-8202, therefore prior to encapsulation a buffer exchange step is 
employed) was added to an aqueous solution of 2-methylimidazole (HMIM, 160 mM, 2ml) 




(Figure 8. 1) resulting in a molar ratio of HMIM:Zn of 4:1205 (2.3 Encapsulation of 
Bm3TE@ZIF-8). All reactions were carried out at room temperature with no stirring and the 
pH after mixing the protein, HMIM and Zn was 9.5.  
 
Figure 8. 1 Encapsulation of Bm3TE within ZIF-8 crystals. 
After 30 min the synthesis solution started to turn cloudy, indicating the formation of a 
Bm3TE@ZIF-8 biocomposite (2.3 Encapsulation of Bm3TE@ZIF-8). The presence of protein 
therefore facilitates the seeding process in ZIF-8 crystals growth. The solution was left 
overnight to enable completion of the reaction. After 24 hours the product was collected by 
centrifugation, washed with ethanol and water and vacuum dried at room temperature (2.3 
Encapsulation of Bm3TE@ZIF-8). The particles obtained were analysed by powder X-ray 
diffraction (PXRD) (Figure 8. 2).  
The absence of the characteristic peak of ZIF-8 at 2θ values of 7.29 and 12.83 ° in the PXRD 
pattern indicated that the formed precipitate did not have the sodalite topology of ZIF-8221. The 
experiment was repeated at the same ratio of HMIM:Zn (160:40 mM) and this time left for 72 
hours to check whether longer ageing the solution assists the formation of ZIF-8201. The 
obtained crystals were centrifuged, washed and characterised with PXRD. However, again, the 
PXRD pattern did not demonstrate the formation of ZIF-8 (Figure A. 1).  
The use of 4:1 ratio of HMIM to Zn in aqueous solution did not form ZIF-8, and an unknown 




shown to require the presence of some organic solvent or the use of the higher ratio of 
HMIM:Zn in an aqueous system255. Therefore, the concentration of the HMIM ligand was 
increased, while the rest of the conditions of the reaction were maintained. Higher ratios of 
HMIM:Zn (8:1, 16:1 and 30:1) were assessed to see if these would result in the formation of 
ZIF-8 in the presence of the Bm3TE protein. The resulting crystals in these experiments were 
centrifuged, washed (2.3 Encapsulation of Bm3TE@ZIF-8), analysed by PXRD (Figure 8. 2) 
and scanning electron microscopy (SEM) (Figure 8. 3). The PXRD patterns of Bm3TE@ZIF-
8 crystals that precipitated out using the higher concentrations of HMIM (16:1 and 30:1 ratios 
of HMIM:Zn) were in good agreement with the pattern reported in the literature for ZIF-8 
(Figure 8. 2). The characteristic peaks of ZIF-8 at 2θ values of 7.4, 10.4, 12.7, 14.7, 16.4, 18.0, 
22.1, 24.5, 26.7 and 29.6° corresponded to the (011), (002), (112), (022), (013), (222), (114), 
(233), (134) and (044) index planes, respectively203, 265, 266.  
 
Figure 8. 2 PXRD patterns of the simulated ZIF-8 (black) and the crystals obtained through 
encapsulation of Bm3TE with various molar ratio of HMIM:Zn; 4:1 (red), 8:1 (green), 16:1 




To check the morphology and crystal size of ZIF-8, the scanning electron microscopy images 
were studied (2.8 Scanning electron microscopy (SEM). Rhombic dodecahedron crystals were 
obtained for the 16:1 and 30:1 ratios of HMIM:Zn with diameter size of 1.2 μm and 0.6 μm 
respectively. This further evidenced the successful formation of ZIF-8 in the presence of 
Bm3TE. However, the scanning electron microscopy image of 8:1 ratio showed a mixture of 
other crystals with different morphology (Figure 8. 3). 
Encapsulation of Bm3TE was therefore carried out using a 16:1 ratio of HMIM:Zn overnight. 
To confirm the success of Bm3TE immobilisation in ZIF-8 crystals, the reaction mixture was 
centrifuged, and the UV-vis absorbance of the supernatant was measured to check for the 
presence of P450Bm3 in the solution. The supernatant after centrifugation did not show the 
characteristic P450 Soret peak at 418 nm, which inferred the absence of the P450Bm3TE haem 
domain protein. 
 
Figure 8. 3 Different resolutions of scanning electron microscopy images of crystals obtained 
by a) 8:1, b) 16:1 and c) 30:1 ratio of HMIM:Zn. The top images are at a higher magnification 
that demonstrates the rhombic dodecahedron crystals and the low magnification images on 




To determine the spatial distribution of Bm3TE within the ZIF-8 crystals, Bm3TE was labelled 
with fluorescein isothiocyanate (FITC) and analysed by confocal laser microscopy (CLSM) 
(2.9 Fluorescein isothiocyanate-tagged Bm3TE). FITC labelled P450 Bm3TE (FITC-Bm3TE) 
molecules were synthesised and encapsulated in ZIF-8 crystals using a previously reported 
method255. In a typical experiment, FITC and Bm3TE were dissolved in carbonate-bicarbonate 
aqueous buffer and left at room temperature in the dark (2.9 Fluorescein isothiocyanate-tagged 
Bm3TE). After 12 hours the FITC tagged Bm3TE (FITC-Bm3TE) was recovered, concentrated 
and washed to remove the excess FITC. Samples prepared using labelled protein were analysed 
by confocal laser microscopy (2.10 Confocal laser scanning microscopy (CLSM)). The images 
showed that the FITC-Bm3TE molecules were associated with the ZIF-8 crystals (Figure 8. 4)  
 
Figure 8. 4 Confocal laser scanning microscopy images demonstrate the co-location of FITC-
Bm3TE and the rhombic dodecahedron ZIF-8 crystals after a Milli-Q H2O and EtOH wash. 
From left to right; fluorescence, bright field, and overlay images of the FITC-Bm3TE@ZIF-8. 
To check the activity of the Bm3TE@ZIF-8, samples were washed with Milli-Q H2O and EtOH 
to remove the loosely adsorbed protein on the crystal surface. Certain P450 enzymes can 
oxidise indole to indigo in the presence of the H2O2 
267 therefore, the activity of the 
encapsulated Bm3TE as an H2O2-dependent P450 enzyme was investigated with indole in the 




to indigo at pH above 8.0, generating a blue colour in the reaction solution (Figure 8. 5). 
However, Bm3TE@ZIF-8 showed no colour changes in indole turn over.  
 
 
Figure 8. 5 The indole turnover with Bm3TE in the presence of H2O2 at different pHs. A blue 
colour was observed at pH above 8. 
Considering that ZIF-8 has small pore aperture (3.4 Å)167 for substrate diffusion, the large size 
of indole (6.7-6.8 Å) might inhibit its diffusion through the ZIF-8 to reach the active site of 
Bm3TE or product release. Chapter 6 has shown that Bm3TE variant can successfully produce 
styrene oxide. Styrene was chosen as a more reactive substrate to investigate its oxidation with 
Bm3TE@ZIF-8. The encapsulated Bm3TE was washed with Milli-Q H2O and then EtOH to 
remove the excess enzyme from the surface of ZIF-8 before its activity was tested with styrene. 
The H2O2-driven turnover with free Bm3TE oxidised styrene to styrene oxide but the 
encapsulated Bm3TE displayed no activity (Figure 8. 6).  
We then considered two possibilities regarding the lack of enzymatic activity of encapsulated 
Bm3TE with styrene: the first reason could be the inactivation of the enzyme during the 
encapsulation process, and the other reason could be the inaccessibility of enzyme to styrene 





Figure 8. 6 GC-MS analysis the hydrogen peroxide driven turnovers of styrene with free 
Bm3TE and Bm3TE@ZIF-8 showed that the encapsulated Bm3@ZIF-8 is not active. 
In terms of inactivation, one hypothesis is that the imidazole based ligands of the ZIF-8 could 
bind to the enzyme haem moeity and inhibit the oxidation activity of Bm3TE. When imidazole 
ligands bind to haem, a type II binding spectrum arises268. Therefore the spin state of Bm3TE 
was measured in the presence of the HMIM ligand (160 mM). No red-shift to ~420 nm was 
observed to indicate that type II binding has occurred (Figure A. 2). However, in order to 
minimise the effect of the high concentration of HMIM (640 mM) used, instead of adding 
Bm3TE to an aqueous solution of HMIM, it was added to the Zn acetate dihydrate solution. 
Also to eliminate the possibility that the deactivation of Bm3TE@ZIF-8 is derived from high 
pH, in this experiment pH of the solution mixture was adjusted to 8.0. Using this alternative 
method, the formation of ZIF-8 was confirmed by PXRD (Figure 8. 7), but no product with 
styrene was observed. This enzymatic assay data demonstrated that pH did not inhibit Bm3TE 




have deactivated the enzyme or the loss of activity could be due to hydrophobicity of ZIF-8 
which could interact with Bm3TE and resulted in irreversible deactivation283, 284. 
 
Figure 8. 7 PXRD patterns of Bm3TE@ZIF-8. In this encapsulation process, Bm3TE was 
added to the aqueous Zn solution instead of HMIM to investigate whether the effect of high 
concentration HMIM (640 mM) on inactivation of the enzyme can be reduced. 
ZIF-8 crystals are not stable at pH below 7.0, and they dissociate in solution202. Therefore, to 
investigate whether the encapsulated enzyme was active or the small pore size prohibited 
substrate accessibility, the crystals of Bm3TE@ZIF-8 were dissolved using 0.1 M citric 
acid/sodium citrate aqueous buffer (pH 5.0) to release the enzyme into solution255. The 
dissolved solution of Bm3TE@ZIF-8 passed through a PD-10 desalting column. After washing 
the sample with Milli-Q H2O followed by centrifugation, a red pellet was observed. The red 
colour indicates that denatured haem protein may be present in the pellet. This suggested the 
denaturation of the Bm3TE during the encapsulation or release process may be occurring. For 
further confirmation, the oxidation activity of the released enzyme (supernatant) was tested 




protein could be denatured during the biocomposite synthesis process and this is the reason we 
do not observe activity. 
 
Figure 8. 8 GC-MS analysis of the hydrogen peroxide driven turnovers of styrene with Bm3TE 
free enzyme and the supernatant, which could contain Bm3TE released from ZIF-8. 
In a control experiment the activity of Bm3TE was tested in the presence of 640 mM HMIM 
aqueous solution, the initial pH of this solution was 11.0 which was then adjusted to 9.5 before 
the addition of enzyme using HCl to simulate the condition of ZIF-8 formation. The colour of 
the initial solution of Bm3TE and HMIM is pale red, which arise from the P450 enzyme colour. 
This red colour disappeared after ~2 hours which could indicate denaturation of the enzyme. 
The activity of Bm3TE was tested for the oxidation of styrene, and a lower activity was 
observed after 2 hours treatment of Bm3TE with 640 mM HMIM (Figure 8. 9). 
Another possible reason for inactivation of the enzyme is the hydrophobic nature of ZIF-8. It 
has been shown that enzymes have good affinity for hydrophobic surfaces, this can result in 
conformational changes and their denaturation269, 270. Liang et al. studies showed that 




Therefore, the hydrophobic interaction of ZIF-8 with Bm3TE could result in denaturation and 
activity loss269, 270.  
 
Figure 8. 9 GC analysis of styrene oxidation with Bm3TE showed that enzyme almost lost its 
activity in the presence of 640 mM HMIM 
Encapsulation of Bm3TE in ZIF-8 crystals was investigated, and the PXRD patterns showed 
the successful formation of ZIF-8 in the presence of Bm3TE. However, the encapsulated 
enzyme showed no activity, and it was hypothesised that Bm3TE denatured during the 
biocomposite synthesis process presumably because of either the hydrophobic interaction with 
ZIF-8269, 270 or deactivation in the presence of the high concentration of HMIM. Therefore to 
eliminate the effect of high concentration of HMIM, different ZIFs could be tested. ZIF-90, 
which has a more hydrophilic 2-imidazole carboxaldehyde (HICA) ligands, was studied for 
encapsulation of Bm3TE. Changing the ligand from HMIM to HICA could affect the 
conditions of formation, and reduce the hydrophobicity of the crystals (which has been shown 




8.2 In situ encapsulation of P450 Bm3@ZIF-90 
Given that Bm3TE appeared to lose its activity in a high concentration of HMIM and the 
hydrophobic interactions with ZIF-8 may be problematic, an alternative encapsulation method 
using ZIF-90 was investigated165, 271. The difference between ZIF-8 and ZIF-90 is in the choice 
of the imidazole ligands. While 2-methylimidazole is employed in the synthesis of ZIF-8, the 
formation of ZIF-90 occurs with HICA and the resulting MOF is more hydrophilic (Equation 
8. 2). The pH of HICA ligand solution is around 6.0 which is significantly lower than HMIM 
(11.0).  
Equation 8. 2 ZIF-8 forms with HMIM and for ZIF-90 formation HICA ligands are used. 
 
In a typical experiment, HICA (160 mM) and Zn (NO3)2.6H2O (40mM) were dissolved in 1:1 
v/v of glycerol/water separately. The enzyme was added to the HICA solution followed by 
addition of the aqueous Zn solution (2.4 Encapsulation of Bm3TE@ZIF-90). The pH of the 
reaction mixture was 7.0. The solution turned cloudy immediately after mixing the 
HICA/enzyme and Zn solution indicating formation Bm3TE/ZIF-90 biocomposite. The 
resulting precipitates were centrifuged and collected after 2 hours. The formed crystals were 
washed with H2O and EtOH to remove the loosely adsorbed protein on the crystal surface. ZIF-




(Figure 8. 10). The 2θ values of 7.4°, 10.4°, 12.7°, 14.7°, 16.4°, 18.0°, 22.1°, 24.5°, 26.7° and 
29.6° corresponded to the (011), (002), (112), (022), (013), (222), (114), (233), (134) and (044) 
index planes respectively, were in a good agreement with the reported literature209, 272, 273 
(Figure 8. 10).  
 
Figure 8. 10 The identical PXRD patterns of Bm3TE@ZIF-90 to the simulated patterns shows 
the successful formation of ZIF-90 in the presence of the enzyme. 
The morphology and size of Bm3TE@ZIF-90 was assessed by scanning electron microscopy  
(2.8 Scanning electron microscopy (SEM). The images showed the rhombic dodecahedral 
crystals ZIF-90 in presence of Bm3TE with an average size of 1.4 μm diameter (Figure 8. 11). 
 
Figure 8. 11 Scanning electron microscopy images of Bm3TE@ZIF-90 showed the rhombic 




The location of the enzyme within the ZIF-90 was studied by confocal laser scanning 
microscopy. The FITC labelled Bm3TE (FITC-Bm3TE) molecules were synthesised as before 
(2.9 Fluorescein isothiocyanate-tagged Bm3TE) and encapsulated in ZIF-90 crystals using the 
same method. The confocal laser scanning microscopy images highlighted the distribution of 
FITC-Bm3TE molecules through the ZIF-90 crystals (Figure 8. 12).  
Figure 8. 12 Confocal laser scanning microscopy images demonstrate the FITC-Bm3TE in 
rhombic dodecahedron ZIF-90 crystals after Milli-Q H2O, and EtOH wash. Left to right; 
fluorescence, bright field, and overlay images of the FITC-Bm3TE@ZIF-90. 
The activity of Bm3TE@ZIF-90 was evaluated for the oxidation of styrene, but no product 
formation activity was observed (Figure 8. 14). Therefore, polyvinylpyrrolidone (PVP) was 
added to the reaction mixture during the encapsulation process to investigate whether PVP 
stabilises Bm3TE. PVP is an amphiphilic and non-ionic surfactant274. It acts as a MOF 
nucleating agent and has been used to stabilise nanoparticles against aggregation and to control 
their size and shape within encapsulation process275-277. PVP has been reported to stabilise. 
gold and silver nanoparticles in polar solvents during the formation of MOFs189. It has also 
been used in encapsulation of cytochrome (Cyt c), as a biological agent, in MOFs168, 189. The 
PVP was added to the protein solution prior to adding the HICA ligand solution followed by 




Bm3TE@ZIF-90. The PXRD pattern of Bm3TE@ZIF-90 in the presence of PVP was analysed 
and confirmed the successful formation of ZIF-90 (Figure 8. 13).   
 
Figure 8. 13 PXRD patterns of Bm3TE in presence and absence of PVP in ZIF-90. The run 
time for the Bm3E@ZIF-90 in the presence of PVP was shorter than that shown in Figure 8.10, 
which contributes to the noisier baseline in this PXRD.  
The activity of encapsulated Bm3TE@ZIF-90 in presence and absence of PVP was tested for 
styrene oxidation, and a small peak was observed at 7.68 min (Figure 8. 14). This retention 
time was the same as that of styrene oxide. To confirm the activity of the enzyme, the 
encapsulation of Bm3TE in ZIF-90 was repeated with double concentration of the enzyme and 
its oxidation activity for styrene was tested. In this experiment, the peak at RT: 7.68 min did 
not increase as expected, and no phenylacetaldehyde product was observed. Therefore a control 
experiment was performed to check whether this peak could be a background signal from ZIF-
90. In similar turnover experiments, styrene was added to the buffer in the presence of ZIF-90 
crystals and H2O2 (60 mM) without any Bm3TE, and in another experiment, styrene was added 
to buffer without any ZIF-90 crystals. The peak at 7.68 min was observed in the presence of 





Figure 8. 14 The GC-MS of free enzyme vs the Bm3TE@ZIF-90 in the presence and 
absence of PVP. 
 
Figure 8. 15 The GC-MS analysis of free Bm3TE vs the Bm3TE@ZIF-90 and control of 
styrene turnover with ZIF-90 without enzyme in the presence of H2O2. A peak at 7.68 min was 
observed in all the three experiments concluding ZIF-90. 
The control experiment suggested that the aforementioned peak arises from ZIF-90 and not 
from the oxidation of styrene. A comparison between the mass spectra of the peak from styrene 




product as the m/z at 119 from the styrene oxide was not observed (Figure 1. 16). The m/z at 
96 correlates to the molecular weight of the HICA ligand which could be present from the 
material decomposition or residual ligand from insufficient washing (2.4 Encapsulation of 
Bm3TE@ZIF-90). The mass spectra from the turnover showed a very small peak at m/z 91, 
which could suggest a very low level of product (Figure 1. 16 b). The inability of Bm3TE@ 
ZIF-90 to oxidise styrene in the presence of PVP demonstrated that PVP does not have a 
significant stabilising effect on Bm3TE. 
 
 
Figure 8. 16 The mass spectra of styrene oxide (top) vs the mass spectra of ZIF-90 background 
peak (bottom) with 7.68 min retention time. 
In a control reaction, the encapsulated Bm3TE@ZIF-90 was treated with citrate buffer (pH:5.5) 
to break down ZIF-90 structure and release Bm3TE255. ZIF-90 crystals were left to fully 
dissolve in the buffer resulting in a clear solution. Similar to the released Bm3TE from ZIF-8, 
after centrifugation a red pellet was observed that inferred the presence of Bm3TE haem The 
supernatant of this mixture was tested with styrene but no oxidation activity was observed from 
the released enzyme (Figure 8. 17). 
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Figure 8. 17 GC-MS analysis of free Bm3TE compared to the supernatant which would contain 
Bm3TE released from ZIF-90. The latter showed no activity, which suggests denaturation of 
the Bm3TE enzyme. 
As Bm3TE activity was significantly reduced in the presence of HMIM (Figure 8. 18), the 
activity of free P450 Bm3TE in the presence of zinc acetate dehydrate (Zn(CH3COO)2), and 
HICA in solutions was also tested to check if the existence of this organic ligand affects its 
activity. The concentrations of the Zn(CH3COO)2 and HICA were kept the same as in the 
encapsulation experiment. The oxidation activity of Bm3TE was tested on styrene turnover, 
and after 2 hours only a small amount of product was observed in the presence of the 
Zn(CH3COO)2 and more than half of the activity was lost in the presence of the HICA. This 
inferred the reduction of enzyme activity in the presence of Zn(CH3COO)2 and HICA ligand 





Figure 8. 18 GC analysis of styrene oxidation with Bm3TE in the presence of the 
Zn(CH3COO)2 salt (green) and HICA ligands (red) showed that enzyme had lost most of its 
activity. 
Considering that Bm3TE lost its activity during the encapsulation process, the ZIF-90 and ZIF-
8 crystals were then synthesised in advance for the adsorption of P450 Bm3TE on the external 
surface instead of in-situ encapsulation to limit the effect of Zn salts and ligands (HMIM and 
HICA) also assess if the enzyme was active after surface immobilisation. 
8.3 Surface attachment of Bm3TE on ZIF-8 and ZIF-90 
ZIF-8 and ZIF-90 particles were synthesised in advance using their published methods (2.5 
Pre-synthesised ZIF-8 crystals, 2.6 Pre-synthesised ZIF-90 crystals)253, 254. The PXRD pattern 
of synthesised ZIF-8 and ZIF-90 were in good agreement with the literature165, 203, 265, 266, 278 
(Figure 8. 19). In a typical synthesis, ZIF-8 crystals with a diameter of 100 nm were prepared 
via a mild and facile route reported previously; the zinc nitrate solution (40 mM in methanol) 




temperature overnight under static conditions. The obtained crystals were washed with excess 
methanol and vacuum dried253. For surface adsorption, the prepared ZIF-8 crystals were added 
to the solution of Bm3TE in H2O and left on ice while was gently shaking. To test the activity 
of the enzyme, after 1 hour, a 500 μl sample was taken from the solution and centrifuged to 
remove the supernatant, which would include any unadsorbed enzyme solution. However, the 
ZIF-8 crystals were floating in the enzyme solution, and centrifugation was unable to sediment 
them to check their activity. 
 
Figure 8. 19 PXRD patterns of pre-synthesised ZIF-8 and ZIF-90 crystals are in good 
agreement with the simulated patterns. 
The confocal laser scanning microscopy images of immobilised Bm3TE on pre-synthesised 
ZIF-8 showed that the crystals are very small to observe individually (Figure 8. 20). Organic 
solvents at different concentrations are known to significantly effect on the size of ZIF-8 
crystals199, 279, 280. Using methanol as a solvent in these pre-synthesised experiments could have 
led to smaller size crystals which could not be sedimented from the solution281, 282. Another 




limited its mixing with H2O. ZIF-8 synthesis in H2O could help to obtain bigger crystals for 
the immobilisation of Bm3TE on the surface of ZIF-8295.  
Figure 8. 20 Confocal laser scanning microscopy images demonstrate the FITC-Bm3TE on 
very small ZIF-8 crystals. Left to right; fluorescence, bright field, and overlay images of the 
FITC-Bm3TE on ZIF-8. 
To immobilise Bm3TE on the surface of ZIF-90, MOF particles were synthesised by mixing a 
zinc nitrate solution (40 mM, in 1:1, tert-butanol: Milli-Q H2O) with HICA solution (160 mM, 
in 1:1 glycerol: Milli-Q H2O) and aging at room temperature overnight without agitation, the 
obtained particles were washed with excess methanol and vacuum dried254 (2.6 Pre-synthesised 
ZIF-90 crystals). The synthesised ZIF-90 particles were added to different concentration of 
Bm3TE in water (3- 6 μM) and gently mixed on ice. At various time intervals, 500 μl samples 
of this solution mixture were taken and centrifuged to check the activity of the immobilised 
protein. The UV/Vis analysis of supernatant of these samples after centrifugation showed a 
strong absorbance at 418 nm (Figure 8. 21), which suggested the presence of the Bm3TE in the 
supernatant. To check if Bm3TE is adsorbed on the ZIF-90 crystals, Bm3TE was labelled with 
FITC, and its spatial distribution within the ZIF-90 crystals was analysed using confocal laser 







Figure 8. 21 The UV/Vis of the supernatant of Bm3TE solution after shaking in the presence 
of ZIF-90 (2 hours) showed that most of the protein remained in the solution and was not 
adsorbed on ZIF-90 crystals. 
The confocal laser microscopy images of the ZIF-90 particles after 2h in FITC-Bm3TE solution 
showed the low interaction of Bm3TE on ZIF-90 crystals (Figure 8. 22), suggesting that most, 
if not all the protein remained in the solution and was not absorbed on the surface of ZIF-90. 
This experiment was repeated with more vigorous shaking of the reaction mixture, and the 
same results were obtained. 
Figure 8. 22 Confocal laser scanning microscopy images demonstrate that the FITC-Bm3TE 
did not adsorb on ZIF-90 crystals. Left to right; fluorescence, bright field, and overlay images 




The reaction mixture of Bm3TE and ZIF-90 crystals was centrifuged, and the collected crystals 
were tested with styrene no styrene oxide or phenylacetaldehyde product was observed (Figure 
8. 23).  
 
Figure 8. 23 GC analysis of styrene oxidation with immobilised Bm3TE on ZIF-90 shows no 
product (red).* is the signal from HICA in ZIF-90 as discussed earlier. 
Overall our experiments for in-situ encapsulation of Bm3TE in ZIF-8 and ZIF-90 crystals did 
not appear to be successful for the oxidation of styrene. In the future substrates with a smaller 
molecular diameter than styrene could be employed to check if  diffusion through the ZIF-8 
pores was problematic. Some modification on Bm3TE may be required to enable its 
encapsulation without deactivation of the enzyme. Functionalisation of ZIF-8 particles may 
increase their interaction with Bm3TE to assist immobilisation. Studies of Madigan et al. 
showed that the increasing negative charge of the surface facilitates the encapsulation of 
Haemogolobin and Myoglobin in ZIF-8283. The reaction of lysine residues with succinic or 
acetic anhydride decreased the pI value and induced the formation of ZIF-8 due to an increase 




Bm3TE on ZIF-8, larger crystals of ZIF-8 may be required to adsorb Bm3TE and help the 
surface adsorption270. Alternatively, to avoid imidazole ligands, metal azolate framework 
(MAF-7) can be employed. MAF-7 are Zn 2+ based framework and has 3-methyl-1,2,4-triazole 
(C3H5N3) as ligands. MAF-7 is more hydrophilic than ZIF-8 therefore hydrophobic interactions 
with the enzyme are reduced256. Hydrogen bonded organic frameworks (HOFs) are a new class 
of frameworks that can be employed for encapsulation. HOFs form by the self-assembly of 
organic molecules via hydrogen-bonding interactions284. The metal-free, low-density porous 
media and biocompatibility make HOFs suitable candidates for immobilisation of enzyme284.  
Overall the inactivation of Bm3TE in the process of encapsulation appears to be one reason for 
lack of activity. Therefore, instead of using organic/inorganic materials, bacterial 
compartments were studied in an attempt to encapsulate P450Bm3. 
8.4 Encapsulation of P450Bm3R19 in bacterial encapsulins 
Because P450Bm3 was thought to be deactivated in the presence of organic ligands during 
previous attempts at encapsulation using MOFs, we sought an alternative method for 
encapsulating these enzymes that could be performed under non-denaturing biocompatible 
conditions. Encapsulins are the smallest members of bacterial microcompartments composed 
of protein cages, which have a very flexible assembly mechanism that has previously been used 
for encasing enzymes285 (1.9.2 Bacterial compartments). Encapsulins have a conserved peptide 
sequence at C-terminal that composed of 30-40 amino acids. This peptide sequence interacts 
with a hydrophobic binding pocket inside the encapsulin, which acts as an anchor for 
orientation of the native cargo protein. This peptide sequence can be used to package non-
native cargo protein inside encapsulin (Figure 8. 24). Therefore, non-native cargo proteins can 
be packaged into encapsulins via fusion of this C-terminal peptide to their C-terminal285, 286. 




peroxidase (DyP) and ferritin-like protein (Flp)240, both of which have a C-terminal peptide 
consisting of 10-40 amino acids. These targeting regions are rich in alanine, proline and 
glycine; and most have a single or double glycosphingolipid (GSL)-binding motif as an anchor 
sequence251. The interactions between the C-terminal extension and encapsulin include salt 
bridges, shape complementarity and hydrophobic interactions 240(Figure 8. 24).  
 
Figure 8. 24 Fusion of a peptide tag on the C-terminal of a non-native cargo protein leads to 
its in vivo packaging inside encapsulin compartments. 
In the present study, two encapsulin proteins expressed in Thermotoga maritima (Tm) and 
Myxococcus xanthus (Mx) were employed to package the P450Bm3R19 variant (1.9.2 
Bacterial compartments, Figure 8. 25). To achieve this, the Bm3R19 plasmid was tagged with 
short targeting peptides (TPs) of the natural cargo protein for Tm and Mx encapsulins by Dr 





Figure 8. 25 Thermotoga maritima (Tm) and Myxococcus xanthus (Mx) are employed for the 
packaging of P450Bm3R19. This figure is from “Encapsulins: microbial nanocompartments 
with applications in biomedicine, nanobiotechnology and materials science” by Giessen251. 
Co-expression and self-assembly of Bm3R19 and Tm encapsulin was achieved using two 
plasmids: one containing the Bm3R19 gene tagged with the natural cargo targeting peptide of 
the Tm encapsulin, and the other containing the gene coding for the Tm encapsulin protein 
itself (Bm3R19TmTP and TmEnc plasmids, respectively). The modified form of the enzyme 
Bm3R19TmTP was assessed as a whole-cell biocatalyst using the oxidation of isophorone. It 
was found to successfully generate 4-hydroxyisophorone to similar levels to those reported in 
Chapter 5 suggesting that this P450Bm3 variant was active. In a typical experiment, cells 
containing both plasmids were grown on an LB plate in the presence of ampicillin and 
streptomycin (2.12 Encapsulation of Bm3R19 in Mx and Tm encapsulins). LB media was 
inoculated with a single colony, and after 6 hours, isopropyl-β-D-thiogalactopyranoside (IPTG) 
added to induce expression of tagged Bm3R19. Cells were incubated for 3 hours before 
pelleting by centrifugation. The cell pellet was then resuspended in LB and induced with 
arabinose to express TmEnc as capsids which would package the Bm3R19 enzyme. The 
overnight culture was pelleted and cells lysed as described in (2.12 Encapsulation of Bm3R19 
in Mx and Tm encapsulins). Polyethylene glycol is commonly used for the precipitation of 
biological microstructures from cells by removing the protective water layer surrounding the 
plasmid287-289. Therefore, Tm encapsulin compartments were precipitated by the addition of 12 
% PEG 8000 to the cell lysate after 30 min252. The resulting precipitate, which presumably 
contained Bm3R19TmTP encapsulated in TmEnc, was isolated by centrifugation and the 
supernatant kept for subsequent activity tests. The isolated encapsulin compartments were 
washed with Tris buffer and centrifuged to remove excess PEG 8000 (2.12 Encapsulation of 




chromatography (SEC) and the UV-absorbing fractions that eluted after the void volume were 
concentrated and washed for further purification via anion exchange chromatography (IEX). 
The fractions containing protein obtained after size exclusion chromatography did not bind to 
the anion exchange column and we assumed that a high concentration of salt (presumably 
residual NaCl and PEG 8000) might have inhibited the encapsulin’s binding. Therefore, the 
crude enzyme was washed with additional Tris buffer (×3) to remove all the adsorbed salt from 
the surface of enzyme before reattempting anion exchange chromatography. After these steps, 
the enzyme showed lower conductivity (less than 1 mS cm-1) during the chromatography steps, 
which infers lower salt in the protein solution. However, the protein again failed to bind the 
column. Therefore, its activity for the oxidation of isophorone was tested without further 
purification, but very low activity was observed (Figure 8. 26). However, the supernatant, 
which was kept after the addition of PEG 8000 to cell generated the isophorone oxidation 
product 4-hydroxyisophorone (4-HIP), suggesting it contained Bm3R19 (Figure 8. 26). 
 
Figure 8. 26 GC-MS analysis of isophorone oxidation by Bm3R19 encapsulated in TmEnc 




whereas incubation of isophorone with the supernatant collected after addition of PEG 8000 
(red) generated significant quantities of 4-hydroxyisophorone (4-HIP). 
The observation of oxidation activity towards 4-HIP by the PEG 8000 supernatant but not the 
precipitate suggests that Bm3R19 was successfully expressed but not encapsulated by TmEnc. 
Therefore, attempted co-expression of Bm3R19 and TmEnc was repeated to check if an 
increase in the ratio of encapsulin to cargo could improve the efficiency of enzyme packaging. 
This was achieved by decreasing the concentration of added IPTG (to induce less Bm3R19 as 
cargo protein) with otherwise identical experimental conditions. PEG 8000 was again added to 
the cell lysate but the mixture incubated for a longer time (50 min) to maximise the amount of 
encapsulin precipitated. Following centrifugation and washing to remove the excess PEG 8000, 
the resulting encapsulin fraction was purified by size exclusion chromatography and its 
oxidation activity towards isophorone determined. However, changing the concentration of 
Bm3R19 appeared to have no effect on its encapsulation as again no oxidation activity was 
observed. 
It is possible that the small compartment size of Tm (20 nm diameter) (Figure 8. 25) inhibited 
packaging of Bm3R19 into the encapsulin. Therefore, we attempted to employ the Mx 
encapsulin (MxEnc), which has a larger size (30 nm diameter) (Figure 8. 25), for the 
encapsulation of Bm3R19. The Bm3R19 plasmid was tagged with the MxEnc TP 
(Bm3R19MxTP) and co-expressed with the MxEnc plasmid in cells grown on an LB plate in 
the presence of ampicillin and streptomycin. In a similar method to the encapsulation of 
Bm3R19 in TmEnc, cells were first induced with IPTG (to express Bm3R19) followed by 
arabinose induction to express the encapsulin protein. The overnight growth was centrifuged, 
and PEG 8000 was added to the cell lysate. Because MxEnc is a larger encapsulin it required 




variant. The precipitated encapsulin compartments were isolated by centrifugation and washed 
to remove adsorbed salts before purification via size exclusion chromatography (Figure 8.27)  
All fractions with UV absorbance at 280 nm, excluding the void volume of the column were 
collected (Figure 8.27), washed with Tris buffer (×3) and concentrated for further purification. 
The concentrated enzyme was loaded to the anion exchange column but did not bind to the 
column. 
 
Figure 8.27 Fast protein liquid chromatography purification of encapsulated Bm3R19MxTP 
in MxEnc with size exclusion chromatography (S500 column). Fractions 10-12 were collected 
for further purification via IEX chromatography. 
The SDS-PAGE analysis of collected fractions (10-12), which were assumed to contain 
Bm3R19 encapsulated in MxEnc, was performed) after size exclusion purification (2.13 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)). In all fractions, a 
clear band was observed at 32 kDa, which corresponded to the encapsulin monomer. However, 
no band corresponding to the 119 kDa Bm3R19 enzyme was observed (Figure 8. 28), which 
suggests that there was an absence, or a negligible amount, of Bm3R19 inside the encapsulin 
compartments. However, the PEG 8000 supernatant demonstrated a band at 119 kDa, which 






Figure 8. 28 SDS-PAGE of collected fractions (Fr 10-12) after attempted encapsulation of 
Bm3R19 in MxEnc. a) 1:10 and 1:2 dilution of Fr 10, b) 1:10, 1:5, 1:2 dilution of Fr 11, c) 1:10 
and 1:2 dilution of Fr 12 and d) 1:10 and 1:2 dilution of the supernatant. All fractions showed 
the same pattern with a clear band at 32kDa corresponding to encapsulin monomers. The 1:2 
dilution of the supernatant demonstrated a band at 119 kDa, which indicated the presence of 
Bm3R19. 
Since further purification of the enzyme by anion exchange column was not possible, the 
oxidation activity of the crude enzyme after size exclusion chromatography purification was 
tested with isophorone. Very low levels of activity were observed that could be from the 
control. However, the supernatant (after PEG 8000 incubation and centrifugation) generated 





Figure 8. 29 GC-MS analysis of the isophorone oxidation by combined size exclusion 
chromatography fractions thought to contain Bm3R19MxTP encapsulated in MxEnc showed 
almost no 4-HIP generation (black), whereas the supernatant (red) generated more product. 
The low level of activity, which might be from the control, could indicate that only a small 
portion of Bm3R19MxTP was encapsulated in MxEnc. Another reason could be the early 
dissociation of encapsulin compartments that may lead to the release of cargo285. Furthermore, 
this observation is in agreement with the SDS-PAGE analysis as no clear band corresponding 
to Bm3R19 was observed in the fractions, which could suggest an inefficient encapsulation 
process.  
In a control experiment, Bm3R19MxTP was expressed without MxEnc to assess its effect on 
the composition of the PEG precipitate. After expression of tagged Bm3R19, 10 % PEG 8000 
was added to the cell lysate, and the mixture centrifuged after incubating for 40 min. The 
isolated enzyme was purified by size exclusion chromatography, and the fractions with UV 





Figure 8. 30 Fast protein liquid chromatography purification of Bm3R19 (without MxEnc co-
expression) using size exclusion chromatography. Fractions with UV absorbance (Fr 12-14) 
were collected to test their oxidation activity towards isophorone. 
The activity of these fractions was tested individually, to identify which fractions contained 
Bm3R19. Almost no activity was observed for any of the collected fractions. However, low 
levels of product was observed for the crude Bm3R19 prior to size exclusion chromatography 
purification, which suggests that the observed activity could arise from Bm3R19 adsorbed on 





Figure 8. 31 GC-MS analysis of isophorone oxidation by individual fractions after size 
exclusion purification (Fr 12-14). Fractions 12 (black), 13 (blue) and 14 (orange) generated 
almost no product. A low level of 4-HIP was observed for the crude enzyme before size 
exclusion chromatography (green). However, the supernatant (red) showed good activity. 
(Crude enzyme is the PEG precipitation before size exclusion chromatography and supernatant 
is the supernatant after addition of PEG 8000 and centrifugation).  
The 5-10 Å sized pores in encapsulins should enable the diffusion of small substrates into and 
out of the compartment252. Considering that the interaction between the cargo and shell could 
destabilize encapsulin compartments290, early dissociation of capsid could happen. 
The active supernatant after PEG precipitation showed that Bm3R19 was successfully 
expressed. Therefore, one probable reason for not observing activity is the absence of Bm3R19 
in the encapsulin compartments, due to inefficient encapsulation of the enzyme. Hence, further 
investigation is required to determine an effective method for the encapsulation of Bm3R19 




modification to provide a better anchoring effect. The expression conditions could also be 
altered to assist in encasing the enzyme. The large size of Bm3 as a dimer may be prohibited 
its packaging inside Mx encapsulin, or the required interactions for active Bm3 dimer 
formation may be perturbed. Another reason for not observing activity might be the effect of 
PEG precipitation on the activity of Bm3. To limit this effect, other purification methods could 








The rate accelerating variants KT2 (A191T/N239H/I259V/A276T/L353I), RLYFIP 
(R47L/Y51F/I401P), and R19 (R47L/Y51F/H171L/Q307H/N319Y) increased product 
formation compared to the WT enzyme, presumably because of their catalytically ready 
conformations. Likewise, the addition of decoy molecules to the WT enzyme improved 
formation rates by inducing a catalytically ready conformation and the combination of decoy 
molecules with the rate accelerating variants further increased productivity, while maintaining 
the regioselectivity. In general the best decoy molecule evaluated was PFC10; however, the 
KT2 variant showed higher coupling efficiency with PFC9. In certain instances the 
stereoselectivity was slightly improved with addition of decoy molecules; for example, during 
the oxidation of ethylbenzene by WT Bm3, the addition of PFC10 enhanced the enantiomeric 
excess from 48 % to 68 % (R). The highest activity was observed in the oxidation of n-
propylbenzene, presumably because the longer chain of n-propylbenzene assisted in the correct 
positioning of the substrate within the active site. Therefore, the addition of decoy molecules 
was not as effective in increasing turnover activity of this substrate, compared to ethylbenzene. 
The major product for ethylbenzene and n-propylbenzene was oxidation of the benzylic C-H 
bond. Despite the higher activity of alkenes compared to alkanes, less epoxide formation was 
observed predominantly due to a lower coupling efficiency. Given that epoxidation is more 
energetically favourable than hydroxylation, this reduced activity could be due to the rigid 
structure of the double bond, which limits substrate mobility in the active site. 
The results presented here showed how the different positions and properties of substituents on 
the benzene ring affect the regioselectivity of P450Bm3 in the oxidation of substituted benzene. 




those containing R47L/Y51F mutations showing the highest oxidation activity because of 
improved uptake of hydrophobic substrates into the access channel. Regioselectivity was 
almost maintained for the variants; however, the for 3-ethyltoluene oxidation, the 
R47L/Y51F/A330P variant provided different product distributions compared to the other 
enzymes and generated 2-ethyl-4-methylphenol as a single product, despite the presence of the 
more reactive benzylic C-H bonds. 
Variants of P450Bm3 were able to regio- and stereoselectively oxidise isophorone to (R)-4-
hydroxyisophorone. The RLYFIP and GVQ (A74G/F87V/L188Q) variants provided the 
highest product formation and showed a 280-fold increase in oxidation activity over the WT 
enzyme. The combination of decoy molecules with these variants further improved product 
formation. However decoy molecules inhibited the activity of the GVQ variant due to the F87V 
mutation in the substrate access channel, which must alter the binding of the decoy molecules 
resulting in lower activity 
The formation of cyclic alcohols from the corresponding cycloalkanes (C5-C10) using WT 
P450Bm3 was very low; however, the addition of decoy molecules significantly improved their 
formation rates. By increasing the size of the decoy molecule, higher activity was achieved 
with both WT and PFC10, including a more than 3000-fold increase in cyclohexane 
hydroxylation by the latter. Cyclooctane demonstrated the highest product formation, its size 
must be optimal for the access channel of the enzyme. The combination of the RLYFIP enzyme 
variant with the PFC10 decoy was the best biocatalyst for the hydroxylation of all cycloalkanes. 
However, results for the GVQ variant were contradictory to those of the other variants in that, 
as with isophorone, its activity was reduced by the addition of decoy molecules. These findings 
likely result from a different substrate binding orientation above the haem in the substrate 




for the hydroxylation of smaller substrates (cyclopentane and cyclohexane) generated more 
product, which provides an insight as to how the combination of different sizes of decoy and 
substrate influence the activity of these enzymes. These results highlight that optimal catalytic 
activity requires the tuning of enzyme mutations along with the size of substrate and decoy 
molecules. 
Oxidation of ethylbenzene, styrene and methylthiobenzene in the presence of H2O2 was 
successful using the Bm3TE variant, whereas the WT and R19 holoenzymes showed no 
activity with the peroxide shunt mechanism. Selectivity was almost maintained for the 
oxidation of these substrates by Bm3TE, with the exception of ethylbenzene, which showed 
different stereoselectivity and favoured formation of the (S) enantiomer (in contrast to the 
holoenzymes, which generated more of the (R) enantiomer). This variant presented higher 
activity in the oxidation of methylthiobenzene over ethylbenzene and styrene. In contrast, the 
holoenzymes were more active in the hydroxylation of ethylbenzene, which infers the 
involvement of a different rate-determining step in the H2O2 shunt mechanism. Furthermore, 
the addition of decoy molecules did not improve the product formation rate, which again 
suggests a different pathway, however further studies are required to fully understand the 
differences in oxidation activity. Second-generation decoy molecules significantly improved 
the formation rates of all products and their combination with the R19 holoenzyme variant 
providing the highest formation rates. 
To improve the the catalytic efficiency of Bm3TE, its immobilisation in ZIF-8 and ZIF-90 was 
studied. The formation of ZIF-8 crystals in the presence of the Bm3TE was successful; 
however, the enzyme lost almost all activity, presumably because of the high concentration of 
HMIM and its interaction with the hydrophobic ZIF-8 molecules. Hence, ZIF-90 with HICA 




no activity was observed, which suggests that Bm3TE was deactivated during the encapsulation 
process. The enzyme’s immobilisation on the surface of pre-synthesised ZIF-8 and ZIF-90 was 
tested and it was found that immobilisation of Bm3TE on the surface of ZIF-8 was inefficient 
and that ZIF-90 crystals showed no affinity for the enzyme. Further studies that involve 
functionalisation of Bm3TE may provide a route to its efficient immobilisation on ZIF-8 and 
ZIF-90 crystals. Alternatively, the application of more hydrophilic frameworks, such as MAF-
7 with 3-methyl-1,2,4-triazolate ligands, or metal-free HOFs could provide more effective 
platforms for an encapsulation strategy. 
Since the organic ligands in MOFs affect the activity of enzyme, its encapsulation under 
biocompatible conditions was performed. As an alternative approach to molecular frameworks, 
we investigated the application of bacterial compartments for the encapsulation of Bm3R19. 
Thermotoga maritima (Tm) and Myxococcus xanthus (Mx) encapsulins were employed as 
capsids with Bm3R19 as a cargo. Based on the absence of oxidation activity of Bm3R19TmTP 
towards isophorone, we postulated that the small size of the TmEnc encapsulin inhibited 
encasing of Bm3R19. Encapsulation using MxEnc, which forms encapsulins with a larger pore 
size, was therefore attempted; however, almost no isophorone oxidation by Bm3R19MxTP was 
observed, indicating similarly inefficient encapsulation of enzyme. Further studies are therefore 
required to determine the factors that influence the encapsulation of Bm3R19 using encapsulins 
and to establish methods, such as modification of the C-terminal peptide tag, for their effective 
encapsulation and isolation of active complexes. 
Overall, the catalytic activity of P450Bm3 was improved by employing enzyme mutagenesis 
and addition of decoy molecules. It has been demonstrated that rate accelerating variants 
significantly increased product formation while maintaining selectivity. With the exception of 




activity. A single T268E mutation converted P450Bm3 to a H2O2- dependent variant and 
subsequently reduced the expense associated with using NADPH. Lastly, to improve thermal 
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Figure A. 1 PXRD patterns of the simulated ZIF-8 (black) vs the crystals obtained through 
encapsulation of Bm3TE with 4:1 molar ratio of HMIM:Zn, after 72 hours aging (red). 
 
Figure A. 2 Spin state shift of P450Bm3TE in the presence of HMIM (160 mM) 
 
